

South Dakota Department of Social Services

Medicaid P&T Committee Meeting

December 4, 2015

DSS 
Strong Families - South Dakota's Foundation and Our Future



DEPARTMENT OF SOCIAL SERVICES

MEDICAL SERVICES

700 Governors Drive

Pierre, South Dakota 57501-2291

(605) 773-3495

FAX (605) 773-5246

**SOUTH DAKOTA
MEDICAID P&T COMMITTEE MEETING
AGENDA**

Friday, December 4, 2015

1:00 – 3:00 PM

DDN Locations:

Sioux Falls

University Center

Room FADM253

4801 North Career Avenue

Pierre

Capitol Building

DDN Room A

500 E Capitol

Rapid City

Black Hills State University

Room UC113

4300 Cheyenne Boulevard

Call to order

Approval of minutes of previous meeting

Prior authorization update

Review of top 15 therapeutic categories/top 50 drugs

Review of drug spend

Patent expirations

Old business

Orkambi form

IBS form

PCSK9 form

Review of antipsychotic prior authorization data

Review of proton pump inhibitor utilization

New business

Review of Enbrel and Humira

Review of Lyrica utilization

Review of Hydrocodone/APAP trend

Review of Otrexup

Review of Durlaza

Oral presentations and comments by manufacturers' representatives

Next meeting date/adjournment

**Minutes of the September 4, 2015
Pharmacy & Therapeutics (P&T) Committee Meeting
South Dakota Department of Social Services, Division of Medical Services**

Members present

Bill Ladwig, RPh; Michelle Baack; Mikel Holland; Richard Holm; Dana Darger; James Engelbrecht

DSS staff present

Mike Jockheck, RPh

Administrative business

The P&T meeting was called to order by M. Baack at 1:00 p.m. The minutes of the June 5, 2015 meeting were presented. B. Ladwig made a motion to approve. R. Holm seconded the motion. The motion was approved unanimously.

Review of Orkambi

A motion was made by M. Baack to move Orkambi to the first of the agenda for discussion. R. Holm seconded the motion. The motion was approved unanimously. The committee reviewed Orkambi clinical information. James Wallace, practicing physician, spoke on behalf of Orkambi. A motion was made by J. Engelbrecht to place Orkambi on prior authorization with criteria including specialist involved in therapy and genotyping. R. Holm seconded the motion. The motion was approved unanimously.

Prior authorization update and statistics

The committee reviewed the prior authorization (PA) activity for July 2015. There were a total of 3,052 PAs processed in the month of July, with 99.90% of those requests responded to in less than eight hours. There were 2,377 requests (78%) received electronically and 675 requests (22%) received by fax.

Analysis of the top 15 therapeutic classes

The committee reviewed the top 15 therapeutic classes by total cost of claims from 04/1/2015 – 06/30/2015. The top five classes were antipsychotics, respiratory and CNS stimulants, amphetamines, insulins, and central nervous system agents, misc. The top 15 therapeutic classes make up 37.94% of total claims. The committee also reviewed the top 50 drugs based on total claims cost and number of claims. The top 50 drugs by claims cost make up 20.41% of total claims. The committee asked for a review of antipsychotic data, Lyrica data, Enbrel/Humira data, and a trend of hydrocodone/APAP data for the December meeting.

Akynzeo second review

The committee reviewed the prior authorization form provided for Akynzeo. There was no public comment. B. Ladwig made a motion to approve the form. J. Engelbrecht seconded the motion. The motion was approved unanimously.

Nuessa second review

The committee reviewed the prior authorization form provided for Nuessa. There was no public comment. J. Engelbrecht made a motion to approve the Nuessa form. R. Holm seconded the motion. The motion was approved unanimously.

Medications used to treat irritable bowel syndrome (IBS) review

The committee reviewed clinical information for medications used to treat IBS. Taylor Bradshaw, representing Allergan, addressed the committee. The committee requested that a form be developed and brought back to the December meeting.

SGLT2 review

The committee reviewed SGLT2 clinical information. There was no public comment. The committee tabled this topic.

DPP-4 review

The committee reviewed DPP-4 clinical information. There was no public comment. The committee tabled this topic.

Glyxambi review

The committee reviewed Glyxambi clinical information. M. Dunze, representing Boehringer Ingelheim, addressed the committee. The committee tabled this topic.

Entresto review

The committee reviewed Entresto clinical information. Kori Hack, representing Novartis, addressed the committee. The committee tabled this topic.

Corlanor review

The committee reviewed Corlanor clinical information. Amanda Champ, representing Amgen, addressed the committee. The committee tabled this topic.

PCSK9 review

The committee reviewed PCSK9 inhibitors clinical information. Amanda Champ, representing Amgen, addressed the committee. The committee requested that a form be developed and brought back to the December meeting.

The next meeting is scheduled for December 4, 2015. B. Ladwig made a motion to adjourn the P&T Committee meeting. R. Holm seconded the motion. The motion passed unanimously and the meeting was adjourned.

**South Dakota Medicaid
Monthly Prior Authorization Report
October 1, 2015 – October 30, 2015**

Time Ratio

Total PAs	Response Under 8 Hours	Response Over 8 Hours	% Under 8 Hours	% Over 8 Hours
3,127	3,085	42	98.66%	1.34%

By Form Type

Form Type	Description	Approve	Deny
ADP	Antidepressant	132	256
AMB	Ambien CR	4	6
ANT	Antihistamines	14	46
APS	Antipsychotic	326	214
ARB	ARBS	2	3
AUB	Aubagio	2	0
COA	Oral Anticoagulants	9	25
DAW	Dispense As Written	5	2
GRA	Gralise	0	1
GRH	Growth Hormone	10	5
GSM	Genitourinary SMR	3	32
HEP	Hepatitis Meds	2	1
HLM	Head Lice Medication	25	19
HOR	Horizant	0	1
LID	Lidoderm	2	56
MAX	Max Units Override	84	1289
NAR	Name Brand Narcotics	2	1
NUC	Opioids	1	3
ONF	Onfi	3	0
OPH	Ophthalmic Antihistamines	0	37
PPI	Proton Pump Inhibitors	49	113
SMR	Skeletal Muscle Relaxants	2	14
STE	Nasal Steroids	10	57
STI	Stimulants	1	6
SUB	Suboxone/Subutex	10	19
TIM	Targeted Immune Modulators	7	6
TOP	Topical Acne Agents	15	93
TRP	Triptans	9	51
ULT	Ultram ER	3	10
XIF	Xifaxan	4	22
XOI	Xanthine Oxidase Inhibitor	1	0
XOL	Xolair	0	2
Totals		737	2390

**South Dakota Medicaid
Monthly Prior Authorization Report
October 1, 2015 – October 30, 2015**

By Request Type

10/01/15 - 10/31/15	# of Requests	Electronic Requests		Faxed Requests	
		#	%	#	%
Prior Authorizations:					
Antidepressant	388	302	78%	86	22%
Ambien CR	10	5	50%	5	50%
Antihistamines	60	48	80%	12	20%
Antipsychotic	540	293	54%	247	46%
ARBS	5	3	60%	2	40%
Aubagio	2	0	0%	2	100%
Oral Anticoagulants	34	26	76%	8	24%
Dispense As Written	7	0	0%	7	100%
Gralise	1	0	0%	1	100%
Growth Hormone	15	4	27%	11	73%
Genitourinary SMR	35	29	83%	6	17%
Hepatitis Meds	3	0	0%	3	100%
Head Lice Medication	44	0	0%	44	100%
Horizant	1	1	100%	0	0%
Lidoderm	58	43	74%	15	26%
Max Units Override	1373	1292	94%	81	6%
Name Brand Narcotics	3	0	0%	3	100%
Opioids	4	3	75%	1	25%
Onfi	3	0	0%	3	100%
Ophthalmic Antihistamines	37	33	89%	4	11%
Proton Pump Inhibitors	162	126	78%	36	22%
Skeletal Muscle Relaxants	16	16	100%	0	0%
Nasal Steroids	67	55	82%	12	18%
Stimulants	7	4	57%	3	43%
Suboxone/Subutex	29	15	52%	14	48%
Targeted Immune Modulators	13	7	54%	6	46%
Topical Acne Agents	108	79	73%	29	27%
Triptans	60	46	77%	14	23%
Ultram ER	13	10	77%	3	23%
Xifaxan	26	19	73%	7	27%
Xanthine Oxidase Inhibitor	1	1	100%	0	0%
Xolair	2	0	0%	2	100%
Prior Authorization Totals	3127	2460	79%	667	21%

**South Dakota Medicaid
Monthly Prior Authorization Report
October 1, 2015 – October 30, 2015**

Electronic PAs (unique)

10/01/15 - 10/31/15	# Unique Approved	# Unique Denied	# Unique Incomplete	Unique Total	Approval %	Total Transactions
Prior Authorizations:						
Antidepressant	91	202	0	293	31.10%	302
Ambien CR	2	3	0	5	40.00%	5
Antihistamines	10	38	0	48	20.80%	48
Antipsychotic	123	157	0	280	43.90%	293
ARBS	0	2	0	2	0.00%	3
Oral Anticoagulants	4	20	0	24	16.70%	26
Growth Hormone	0	4	0	4	0.00%	4
Genitourinary SMR	3	21	0	24	12.50%	29
Horizant	0	1	0	1	0.00%	1
Lidoderm	0	39	0	39	0.00%	43
Max Units Override	37	1165	0	1202	3.10%	1292
Opioids	1	2	0	3	33.30%	3
Ophthalmic Antihistamines	0	33	0	33	0.00%	33
Proton Pump Inhibitors	32	83	0	115	27.80%	126
Skeletal Muscle Relaxants	2	14	0	16	12.50%	16
Nasal Steroids	6	49	0	55	10.90%	55
Stimulants	0	4	0	4	0.00%	4
Suboxone/Subutex	0	15	0	15	0.00%	15
Targeted Immune Modulators	1	6	0	7	14.30%	7
Topical Acne Agents	6	72	0	78	7.70%	79
Triptans	4	42	0	46	8.70%	46
Ultram ER	3	7	0	10	30.00%	10
Xifaxan	0	17	0	17	0.00%	19
Xanthine Oxidase Inhibitor	1	0	0	1	100.00%	1
TOTALS	326	1996	0	2322	14.00%	2460

TOP 50 DRUGS BASED ON NUMBER OF CLAIMS FROM 07/01/2015 - 09/30/2015

Drug	AHFS Therapeutic Class	Rx	Paid	Paid/Rx	% Total Claims
HYDROCODONE-ACETAMINOPHEN	OPIATE AGONISTS	5,723	\$ 132,704.37	\$ 23.19	2.97%
AMOXICILLIN	PENICILLINS	4,923	\$ 41,698.27	\$ 8.47	2.56%
OMEPRAZOLE	PROTON-PUMP INHIBITORS	3,775	\$ 41,616.57	\$ 11.02	1.96%
CETIRIZINE HCL	SECOND GENERATION ANTIHISTAMINES	3,581	\$ 26,165.17	\$ 7.31	1.86%
MONTELUKAST SODIUM	LEUKOTRIENE MODIFIERS	3,401	\$ 70,021.37	\$ 20.59	1.77%
METHYLPHENIDATE ER	RESPIRATORY AND CNS STIMULANTS	3,317	\$ 641,620.24	\$ 193.43	1.72%
FLUOXETINE HCL	ANTIDEPRESSANTS	3,170	\$ 36,132.14	\$ 11.40	1.65%
AZITHROMYCIN	MACROLIDES	2,928	\$ 56,751.03	\$ 19.38	1.52%
TRAMADOL HCL	OPIATE AGONISTS	2,915	\$ 23,875.77	\$ 8.19	1.51%
SERTRALINE HCL	ANTIDEPRESSANTS	2,909	\$ 22,210.63	\$ 7.64	1.51%
LEVOTHYROXINE SODIUM	THYROID AGENTS	2,848	\$ 43,801.12	\$ 15.38	1.48%
VYVANSE	AMPHETAMINES	2,778	\$ 583,000.00	\$ 209.86	1.44%
TRAZODONE HCL	ANTIDEPRESSANTS	2,485	\$ 14,552.80	\$ 5.86	1.29%
LISINAPRIL	ANGIOTENSIN-CONVERTING ENZYME INHIBITORS	2,168	\$ 11,852.25	\$ 5.47	1.13%
LORATADINE	SECOND GENERATION ANTIHISTAMINES	2,128	\$ 12,380.73	\$ 5.82	1.10%
GABAPENTIN	ANTICONVULSANTS, MISCELLANEOUS	2,106	\$ 37,267.83	\$ 17.70	1.09%
DEXTROAMPHETAMINE-AMPHET ER	AMPHETAMINES	2,001	\$ 243,212.97	\$ 121.55	1.04%
VENTOLIN HFA	BETA-ADRENERGIC AGONISTS	1,975	\$ 100,675.73	\$ 50.98	1.03%
CEPHALEXIN	CEPHALOSPORINS	1,922	\$ 31,057.40	\$ 16.16	1.00%
SULFAMETHOXAZOLE-TRIMETHOPRIM	SULFONAMIDES (SYSTEMIC)	1,878	\$ 57,714.29	\$ 30.73	0.97%
FLUTICASON PROPIONATE	CORTICOSTEROIDS (EENT)	1,845	\$ 25,645.89	\$ 13.90	0.96%
GUANFACINE HCL ER	CENTRAL NERVOUS SYSTEM AGENTS, MISC.	1,829	\$ 81,927.56	\$ 44.79	0.95%
CLONAZEPAM	BENZODIAZEPINES (ANTICONVULSANTS)	1,725	\$ 14,062.39	\$ 8.15	0.90%
CLONIDINE HCL	CENTRAL ALPHA-AGONISTS	1,674	\$ 11,045.02	\$ 6.60	0.87%
ALBUTEROL SULFATE	BETA-ADRENERGIC AGONISTS	1,611	\$ 30,455.18	\$ 18.90	0.84%
PROAIR HFA	BETA-ADRENERGIC AGONISTS	1,568	\$ 87,998.58	\$ 56.12	0.81%
PREDNISONE	ADRENALS	1,542	\$ 11,861.90	\$ 7.69	0.80%
POLYETHYLENE GLYCOL 3350	CATHARTICS AND LAXATIVES	1,514	\$ 38,012.35	\$ 25.11	0.79%
IBUPROFEN	NONSTEROIDAL ANTI-INFLAMMATORY AGENTS	1,504	\$ 10,890.67	\$ 7.24	0.78%
METFORMIN HCL	BIGUANIDES	1,485	\$ 10,945.06	\$ 7.37	0.77%
OXYCODONE-ACETAMINOPHEN	OPIATE AGONISTS	1,445	\$ 39,803.55	\$ 27.55	0.75%
CITALOPRAM HBR	ANTIDEPRESSANTS	1,437	\$ 8,499.53	\$ 5.91	0.75%
VITAMIN D2	VITAMIN D	1,393	\$ 8,429.30	\$ 6.05	0.72%
AMOX TR-POTASSIUM CLAVULANATE	PENICILLINS	1,354	\$ 33,762.90	\$ 24.94	0.70%
LORAZEPAM	BENZODIAZEPINES (ANXIOLYTIC, SEDATIVE/HYP)	1,330	\$ 9,491.77	\$ 7.14	0.69%
CYCLOBENZAPRINE HCL	CENTRALLY ACTING SKELETAL MUSCLE RELAXANT	1,324	\$ 8,821.18	\$ 6.66	0.69%
RISPERIDONE	ANTIPSYCHOTIC AGENTS	1,306	\$ 15,190.36	\$ 11.63	0.68%
LAMOTRIGINE	ANTICONVULSANTS, MISCELLANEOUS	1,282	\$ 17,981.62	\$ 14.03	0.67%
TRIAMCINOLONE ACETONIDE	ANTI-INFLAMMATORY AGENTS (SKIN & MUCOUS)	1,270	\$ 20,546.69	\$ 16.18	0.66%
ARIPIRAZOLE	ANTIPSYCHOTIC AGENTS	1,235	\$ 572,533.94	\$ 463.59	0.64%
CEFDINIR	CEPHALOSPORINS	1,180	\$ 58,637.18	\$ 49.69	0.61%
QUETIAPINE FUMARATE	ANTIPSYCHOTIC AGENTS	1,142	\$ 18,716.89	\$ 16.39	0.59%
MUPIROCIN	ANTIBACTERIALS (SKIN & MUCOUS MEMBRANE)	1,125	\$ 24,209.92	\$ 21.52	0.58%
ESCITALOPRAM OXALATE	ANTIDEPRESSANTS	1,053	\$ 10,663.09	\$ 10.13	0.55%
LEVETIRACETAM	ANTICONVULSANTS, MISCELLANEOUS	1,042	\$ 27,276.84	\$ 26.18	0.54%
TOPIRAMATE	ANTICONVULSANTS, MISCELLANEOUS	1,042	\$ 11,846.21	\$ 11.37	0.54%
VENLAFAXINE HCL ER	ANTIDEPRESSANTS	1,035	\$ 21,580.09	\$ 20.85	0.54%
RANITIDINE HCL	HISTAMINE H2-ANTAGONISTS	984	\$ 7,826.52	\$ 7.95	0.51%
SIMVASTATIN	HMG-COA REDUCTASE INHIBITORS	979	\$ 6,632.94	\$ 6.78	0.51%
ALPRAZOLAM	BENZODIAZEPINES (ANXIOLYTIC, SEDATIVE/HYP)	979	\$ 6,606.41	\$ 6.75	0.51%
TOTAL TOP 50		99,165	\$ 3,480,212.21	\$ 35.10	51.48%

Total Rx Claims	192,636
From 07/01/2015 - 09/30/2015	

TOP 50 DRUGS BASED ON TOTAL CLAIMS COST FROM 07/01/2015 - 09/30/2015

Drug	AHFS Therapeutic Class	Rx	Paid	Paid/Rx	% Total Claims	% Total Cost
METHYLPHENIDATE ER	RESPIRATORY AND CNS STIMULANTS	3,317	\$ 641,620.24	\$ 193.43	1.72%	4.00%
VYVANSE	AMPHETAMINES	2,778	\$ 583,000.00	\$ 209.86	1.44%	3.64%
ARIPIRAZOLE	ANTIPSYCHOTIC AGENTS	1,235	\$ 572,533.94	\$ 463.59	0.64%	3.57%
LATUDA	ANTIPSYCHOTIC AGENTS	394	\$ 345,501.27	\$ 876.91	0.20%	2.15%
STRATTERA	CENTRAL NERVOUS SYSTEM AGENTS, MISC.	882	\$ 291,686.88	\$ 330.71	0.46%	1.82%
LYRICA	ANTICONVULSANTS, MISCELLANEOUS	753	\$ 284,907.06	\$ 378.36	0.39%	1.78%
INVEGA SUSTENNA	ANTIPSYCHOTIC AGENTS	153	\$ 248,653.99	\$ 1,625.19	0.08%	1.55%
DEXTROAMPHETAMINE-AMPHET ER	AMPHETAMINES	2,001	\$ 243,212.97	\$ 121.55	1.04%	1.52%
HARVONI	HCV ANTIVIRALS	7	\$ 229,465.90	\$ 32,780.84	0.00%	1.43%
LANTUS SOLOSTAR	INSULINS	540	\$ 224,595.23	\$ 415.92	0.28%	1.40%
SOVALDI	HCV ANTIVIRALS	8	\$ 204,632.80	\$ 25,579.10	0.00%	1.28%
NOVOLOG FLEXPEN	INSULINS	416	\$ 200,173.00	\$ 481.19	0.22%	1.25%
ADVAIR DISKUS	CORTICOSTEROIDS (RESPIRATORY TRACT)	615	\$ 199,124.17	\$ 323.78	0.32%	1.24%
HUMIRA PEN	DISEASE-MODIFYING ANTIRHEUMATIC AGENTS	53	\$ 196,394.04	\$ 3,705.55	0.03%	1.22%
DEXMETHYLPHENIDATE HCL ER	RESPIRATORY AND CNS STIMULANTS	908	\$ 185,430.04	\$ 204.22	0.47%	1.16%
PULMOZYME	MUCOLYTIC AGENTS	58	\$ 167,917.30	\$ 2,895.13	0.03%	1.05%
ENBREL	DISEASE-MODIFYING ANTIRHEUMATIC AGENTS	53	\$ 161,680.14	\$ 3,050.57	0.03%	1.01%
PREVACID	PROTON-PUMP INHIBITORS	420	\$ 160,323.60	\$ 381.72	0.22%	1.00%
NOVOLOG	INSULINS	411	\$ 154,990.36	\$ 377.11	0.21%	0.97%
FLOVENT HFA	CORTICOSTEROIDS (RESPIRATORY TRACT)	776	\$ 151,547.05	\$ 195.29	0.40%	0.95%
RECOMBINATE	HEMOSTATICS	7	\$ 145,531.87	\$ 20,790.27	0.00%	0.91%
COPAXONE	IMMUNOMODULATORY AGENTS	26	\$ 140,232.27	\$ 5,393.55	0.01%	0.87%
ADVATE	HEMOSTATICS	5	\$ 133,386.16	\$ 26,677.23	0.00%	0.83%
HYDROCODONE-ACETAMINOPHEN	OPIATE AGONISTS	5,723	\$ 132,704.37	\$ 23.19	2.97%	0.83%
INVEGA	ANTIPSYCHOTIC AGENTS	114	\$ 119,004.08	\$ 1,043.90	0.06%	0.74%
LEVEMIR FLEXTOUCH	INSULINS	260	\$ 114,727.07	\$ 441.26	0.13%	0.72%
OXYCONTIN	OPIATE AGONISTS	363	\$ 114,468.00	\$ 315.34	0.19%	0.71%
XENAZINE	CENTRAL NERVOUS SYSTEM AGENTS, MISC.	11	\$ 112,912.32	\$ 10,264.76	0.01%	0.70%
LANTUS	INSULINS	274	\$ 109,186.35	\$ 398.49	0.14%	0.68%
SEROQUEL XR	ANTIPSYCHOTIC AGENTS	183	\$ 104,843.60	\$ 572.92	0.09%	0.65%
ONFI	BENZODIAZEPINES (ANTICONVULSANTS)	124	\$ 101,412.99	\$ 817.85	0.06%	0.63%
VENTOLIN HFA	BETA-ADRENERGIC AGONISTS	1,975	\$ 100,675.73	\$ 50.98	1.03%	0.63%
AFINITOR	ANTINEOPLASTIC AGENTS	9	\$ 98,062.91	\$ 10,895.88	0.00%	0.61%
BUDESONIDE	CORTICOSTEROIDS (RESPIRATORY TRACT)	286	\$ 92,169.47	\$ 322.27	0.15%	0.57%
PROAIR HFA	BETA-ADRENERGIC AGONISTS	1,568	\$ 87,998.58	\$ 56.12	0.81%	0.55%
EPIPEN JR 2-PAK	ALPHA- AND BETA-ADRENERGIC AGONISTS	173	\$ 85,020.63	\$ 491.45	0.09%	0.53%
GLEEVEC	ANTINEOPLASTIC AGENTS	7	\$ 82,927.82	\$ 11,846.83	0.00%	0.52%
ADVATE UH	HEMOSTATICS	1	\$ 82,311.20	\$ 82,311.20	0.00%	0.51%
GUANFACINE HCL ER	CENTRAL NERVOUS SYSTEM AGENTS, MISC.	1,829	\$ 81,927.56	\$ 44.79	0.95%	0.51%
GENOTROPIN	PITUITARY	26	\$ 81,840.53	\$ 3,147.71	0.01%	0.51%
NORDITROPIN FLEXPRO	PITUITARY	30	\$ 80,669.66	\$ 2,688.99	0.02%	0.50%
TECFIDERA	IMMUNOMODULATORY AGENTS	14	\$ 80,449.63	\$ 5,746.40	0.01%	0.50%
SPIRIVA	ANTIMUSCARINICS/ANTISPASMODICS	244	\$ 79,888.72	\$ 327.41	0.13%	0.50%
JANUVIA	DIPEPTIDYL PEPTIDASE-4(DPP-4) INHIBITORS	235	\$ 77,494.67	\$ 329.76	0.12%	0.48%
ONETOUCH ULTRA TEST STRIPS	DIABETES MELLITUS	543	\$ 76,177.59	\$ 140.29	0.28%	0.48%
ESOMEPRAZOLE MAGNESIUM	PROTON-PUMP INHIBITORS	290	\$ 72,646.46	\$ 250.51	0.15%	0.45%
MONTELUKAST SODIUM	LEUKOTRIENE MODIFIERS	3,401	\$ 70,021.37	\$ 20.59	1.77%	0.44%
VIMPAT	ANTICONVULSANTS, MISCELLANEOUS	111	\$ 69,353.99	\$ 624.81	0.06%	0.43%
FOCALIN XR	RESPIRATORY AND CNS STIMULANTS	247	\$ 69,231.27	\$ 280.29	0.13%	0.43%
CIPRODEX	ANTIBACTERIALS (EENT)	380	\$ 65,419.91	\$ 172.16	0.20%	0.41%
TOTAL TOP 50		34,237	\$ 8,310,086.76	\$ 242.72	17.77%	51.83%

Total Rx Claims	192,636
From 07/01/2015 - 09/30/2015	
Total Rx Claims Cost	\$16,034,520.25
From 07/01/2015 - 09/30/2015	


**SOUTH DAKOTA MEDICAID
Cost Management Analysis**

TOP 15 THERAPEUTIC CLASSES BY TOTAL COST OF CLAIMS FROM 07/01/2015 - 09/30/2015

AHFS Therapeutic Class	Rx	Paid	Paid/Rx	% Total Claims	% Total Cost
ANTIPSYCHOTIC AGENTS	6,397	\$ 1,707,482.48	\$ 266.92	3.32%	10.65%
RESPIRATORY AND CNS STIMULANTS	5,880	\$ 1,029,140.44	\$ 175.02	3.05%	6.42%
INSULINS	2,428	\$ 1,000,438.79	\$ 412.04	1.26%	6.24%
AMPHETAMINES	5,613	\$ 887,892.65	\$ 158.19	2.91%	5.54%
ANTICONSULSANTS, MISCELLANEOUS	9,103	\$ 823,782.58	\$ 90.50	4.73%	5.14%
CORTICOSTEROIDS (RESPIRATORY TRACT)	2,687	\$ 704,128.35	\$ 262.05	1.39%	4.39%
DISEASE-MODIFYING ANTIRHEUMATIC AGENT	171	\$ 519,777.51	\$ 3,039.63	0.09%	3.24%
CENTRAL NERVOUS SYSTEM AGENTS, MISC.	2,868	\$ 513,529.69	\$ 179.05	1.49%	3.20%
ANTINEOPLASTIC AGENTS	478	\$ 454,525.70	\$ 950.89	0.25%	2.83%
OPIATE AGONISTS	13,103	\$ 440,400.01	\$ 33.61	6.80%	2.75%
HCV ANTIVIRALS	15	\$ 434,098.70	\$ 28,939.91	0.01%	2.71%
HEMOSTATICS	28	\$ 389,084.64	\$ 13,895.88	0.01%	2.43%
PROTON-PUMP INHIBITORS	5,883	\$ 385,850.02	\$ 65.59	3.05%	2.41%
ANTIDEPRESSANTS	17,523	\$ 348,012.09	\$ 19.86	9.10%	2.17%
ANTIRETROVIRALS	259	\$ 327,007.75	\$ 1,262.58	0.13%	2.04%
TOTAL TOP 15	72,436	\$ 9,965,151.40	\$ 137.57	37.60%	62.15%

Total Rx Claims	192,636
From 07/01/2015 - 09/30/2015	
Total Rx Claims Cost	\$16,034,520.25
From 07/01/2015 - 09/30/2015	

**Top 15 Therapeutic Classes
Based on Total Cost of Claims**



SD Medicaid Drug Spend 2012 - 2015

Drug Spend 2012

Total	201201	201202	201203	201204	201205	201206	201207	201208	201209	201210	201211	201212	Row SubTotal
Rx_Dollars	\$4,849,391.09	\$4,997,072.08	\$5,257,537.69	\$4,879,456.62	\$4,919,253.17	\$4,913,164.11	\$3,845,419.78	\$4,863,874.68	\$4,014,447.34	\$4,823,060.40	\$4,576,545.82	\$4,443,459.76	\$56,382,682.54
Rx_Count	77,559	77,426	79,761	74,004	74,773	75,503	57,785	72,290	63,542	77,195	73,717	71,219	874,774
Average_Rx_Cost	\$62.53	\$64.54	\$65.92	\$65.94	\$65.79	\$65.07	\$66.55	\$67.28	\$63.18	\$62.48	\$62.08	\$62.39	\$64.45
Recip_Count	29,127	30,437	29,893	28,110	27,215	23,029	22,803	26,411	25,434	28,741	28,017	27,141	
Recip_Average_Rx_Cost	\$166.49	\$164.18	\$175.88	\$173.58	\$180.76	\$213.35	\$168.64	\$184.16	\$157.84	\$167.81	\$163.35	\$163.72	\$172.76

Drug Spend 2013

Total	201301	201302	201303	201304	201305	201306	201307	201308	201309	201310	201311	201312	Row SubTotal
Rx_Dollars	\$5,098,169.75	\$4,387,497.68	\$3,483,772.72	\$4,587,727.94	\$4,954,424.54	\$4,080,139.76	\$4,746,330.61	\$4,785,381.28	\$4,365,123.88	\$5,013,735.15	\$4,581,524.61	\$4,062,575.21	\$54,146,403.13
Rx_Count	75,726	68,046	54,790	68,602	68,081	57,928	65,533	66,327	62,205	72,336	65,859	56,582	782,015
Average_Rx_Cost	\$67.32	\$64.48	\$63.58	\$66.87	\$72.77	\$70.43	\$72.43	\$72.15	\$70.17	\$69.31	\$69.57	\$71.80	\$69.24
Recip_Count	27,719	25,992	22,293	24,675	24,016	21,412	22,581	23,564	23,754	25,749	24,485	21,798	
Recip_Average_Rx_Cost	\$183.92	\$168.80	\$156.27	\$185.93	\$206.30	\$190.55	\$210.19	\$203.08	\$183.76	\$194.72	\$187.12	\$186.37	\$187.98

Drug Spend 2014

Total	201401	201402	201403	201404	201405	201406	201407	201408	201409	201410	201411	201412	Row SubTotal
Rx_Dollars	\$5,147,300.76	\$5,032,624.29	\$5,434,147.99	\$5,247,611.60	\$5,248,010.35	\$4,405,071.19	\$4,931,375.07	\$4,738,777.48	\$4,538,235.88	\$5,773,974.96	\$5,036,186.43	\$5,931,145.84	\$61,464,461.84
Rx_Count	68,519	68,225	71,659	71,966	67,552	54,782	61,854	61,147	54,408	73,097	63,572	72,538	789,319
Average_Rx_Cost	\$75.12	\$73.77	\$75.83	\$72.92	\$77.69	\$80.41	\$79.73	\$77.50	\$83.41	\$78.99	\$79.22	\$81.77	\$77.87
Recip_Count	25,131	25,541	26,527	25,767	24,324	20,669	22,363	22,719	21,996	25,738	23,583	25,398	
Recip_Average_Rx_Cost	\$204.82	\$197.04	\$204.85	\$203.66	\$215.75	\$213.12	\$220.51	\$208.58	\$206.32	\$224.34	\$213.55	\$233.53	\$212.12

Drug Spend 2015

Total	201501	201502	201503	201504	201505	201506	201507	201508	201509	201510	201511	201512	Row SubTotal
Rx_Dollars	\$6,059,828.77	\$5,587,701.56	\$6,232,984.04	\$5,875,536.95	\$5,531,389.37	\$4,840,508.32	\$5,530,795.23	\$5,565,691.43	\$4,944,208.34	\$5,190,960.78	\$0.00	\$0.00	\$55,359,604.79
Rx_Count	75,401	70,153	77,448	74,554	67,710	57,937	68,133	66,675	57,830	65,920	0	0	681,761
Average_Rx_Cost	\$80.37	\$79.65	\$80.48	\$78.81	\$81.69	\$83.55	\$81.18	\$83.47	\$85.50	\$78.75	\$0.00	\$0.00	\$81.35
Recip_Count	27,982	26,551	28,053	26,841	24,516	21,220	23,087	23,483	22,260	24,368	0	0	
Recip_Average_Rx_Cost	\$216.56	\$210.45	\$222.19	\$218.90	\$225.62	\$228.11	\$239.56	\$237.01	\$222.11	\$213.02	\$0.00	\$0.00	\$223.35

Anticipated Availability of First-Time Generics

—To help explain the benefits of generic drugs to your patients, the FDA has patient education materials available at <http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ucm169209.htm>—

Brand^a (Manufacturer)	Generic Name	Generic Manufacturer(s)^{b,1}	Anticipated Availability^c
<i>Abilify</i> (Otsuka)	Aripiprazole tablet	<u>Tablet</u> : Apotex, Camber (Hetero), Teva, Torrent, Trigen (Alembic)	Generic now available
<i>Acova</i> (Pfizer)	Argatroban 100 mg/mL	Fresenius Kabi, Par	Generic now available
<i>AndroGel 1%</i> (AbbVie)	Testosterone	Perrigo	Generic now available
<i>Angiomax</i> (Medicines Co)	Bivalirudin	Hospira	Generic now available
<i>Atelvia</i> (Warner Chilcott)	Risedronate delayed-release tablet	Teva	Generic now available
<i>Axert</i> (Ortho-McNeil-Janssen)	Almotriptan	Teva	Generic now available
<i>Carac</i> (Valeant)	Fluorouracil cream 0.5%	Spear	Generic now available
<i>Copaxone</i> (Teva)	Glatiramer 20 mg/mL (<i>Glatopa</i>)	Sandoz	Generic now available
<i>Dibenzyline</i> (Wellspring)	Phenoxybenzamine	Roxane	Generic now available
<i>Edecrin</i> (Aton)	Ethacrynate sodium injection	Par	Generic now available
<i>Exforge HCT</i> (Novartis)	Amlodipine/Valsartan/ Hydrochlorothiazide	Lupin, Par, Teva, Torrent	Generic now available

More . . .

Brand^a (Manufacturer)	Generic Name	Generic Manufacturer(s)^{b,1}	Anticipated Availability^c
<i>Femhrt</i> (Warner Chilcott)	Ethinyl estradiol/norethindrone	Glenmark	Generic now available
<i>Fusilev</i> (Spectrum)	Levoleucovorin calcium injection 10 mg/mL (17.5 mL vial)(brand discontinued in this strength)	Sandoz	Generic now available
<i>Generess Fe</i> (Actavis)	Norethindrone, Ethinyl estradiol, Ferrous fumarate	Mylan	Generic now available
<i>Kenalog</i> (Ranbaxy)	Triamcinolone topical spray	Perrigo	Generic now available
<i>Lamictal ODT</i> (GlaxoSmithKline)	Lamotrigine orally disintegrating tablet	Global (Impax)	Generic now available
<i>Lotronex</i> (Prometheus)	Alosetron tablet	Roxane	Generic now available
<i>Lybrel</i> (Wyeth)	Levonorgestrel 0.09 mg/ethinyl estradiol 0.02 mg	Glenmark	Generic now available
<i>Megace ES</i> (Par)	Megestrol acetate oral suspension 125 mg/mL	TWi Pharmaceuticals	Generic now available
<i>Methylin</i> (Mallinckrodt)	Methylphenidate chewable tablet	Gavis (Novel)	Generic now available
<i>Mirapex ER</i> (Boehringer Ingelheim)	Pramipexole extended-release tablet	Par (Anchen)	Generic now available
<i>Namenda</i> (Forest)	Memantine tablet	Amneal, Dr. Reddy's, Lupin, Mylan, Sun, Upsher-Smith	Generic now available
<i>Neupogen</i> (Amgen)	Filgrastim (biosimilar ¹ filgrastim-sndz [Zarxio])	Sandoz	Now available (this product [Zarxio] is a new biosimilar, ¹ not a generic).
<i>Nexium</i> (AstraZeneca)	Esomeprazole magnesium delayed-release capsule	Mylan, Teva (Ivax)	Generic now available
<i>Protopic</i> (Astellas)	Tacrolimus ointment	Fougera	Generic now available
<i>Targretin</i> (Eisai)	Bexarotene	Mylan	Generic now available

Brand ^a (Manufacturer)	Generic Name	Generic Manufacturer(s) ^{b,1}	Anticipated Availability ^c
<i>Testim</i> (Auxilium)	Testosterone transdermal gel (<i>Vogelxo</i>)	Upsher-Smith	Generic now available
<i>Zyvox</i> (Pfizer)	Linezolid injection	Hospira, Teva	Generic now available
<i>Zyvox</i> (Pfizer)	Linezolid tablet	Teva	Generic now available
<i>Abilify</i> (Otsuka)	Aripiprazole orally disintegrating tablet	Alembic	Third quarter 2015 ¹⁰⁵
<i>Integrilin</i> (Schering)	Eptifibatide	Teva	September 2015
<i>Emend</i> (Merck)	Aprepitant capsule	Sandoz	Fourth quarter 2015 ¹¹³
<i>Namenda</i> (Forest)	Memantine oral solution	Silarx	October 2015
<i>Asacol HD</i> (Warner Chilcott)	Mesalamine delayed-release tablet	Zydus ^{f,90}	November 2015 ⁹⁰
<i>Avodart</i> (GlaxoSmithKline)	Dutasteride	Actavis, Amneal, Apotex, Banner, Endo, Roxane, Sandoz, Teva	November 2015
<i>Frova</i> (Endo)	Frovatriptan	Mylan	November 2015
<i>Jalyn</i> (GlaxoSmithKline)	Dutasteride/Tamsulosin	Actavis, ^{h,13} Anchen, Impax, ^{h,13} Mylan ^{h,13}	November 2015 ^d
<i>Patanol</i> (Alcon)	Olopatadine 0.1% ophthalmic solution	Actavis, Apotex, Sandoz, Wockhardt	December 2015
<i>Ritalin LA</i> (Novartis)	Methylphenidate extended-release capsule	Actavis, Teva	December 2015 ^{e,38}
<i>OxyContin</i> (Purdue)	Oxycodone extended-release tablet (new formulation)	Impax, Mallinckrodt, Par, Teva	January 2016 ¹²
<i>Gleevec</i> (Novartis)	Imatinib	Apotex, Sun	February 2016 ²⁴
<i>Glumetza</i> (Santarus)	Metformin extended-release tablet	Lupin, ^{f,17} Sun	February 2016 ¹⁷

Brand ^a (Manufacturer)	Generic Name	Generic Manufacturer(s) ^{b,1}	Anticipated Availability ^c
<i>Enablex</i> (Novartis)	Darifenacin	Anchen	March 2016 ⁹⁷
<i>Epzicom</i> (GlaxoSmithKline)	Abacavir sulfate/Lamivudine	<u>Tablet</u> : Aurobindo, Cipla, Hetero, Matrix, Mylan, Teva <u>Tablet for Suspension</u> : Cipla, Mylan	March 2016 ⁹⁷
<i>Crestor</i> (AstraZeneca)	Rosuvastatin calcium	Actavis, Apotex, Aurobindo, Glenmark, Mylan, Par, Sandoz, Sun, Teva, Torrent	May 2016 ²⁶
<i>Lantus</i> (Sanofi-Aventis)	Insulin glargine	Eli Lilly/Boehringer Ingelheim	Mid-2016 ¹⁰⁹ (This product will be a new brand of insulin glargine [<i>Basaglar</i>], not a generic.)
<i>Cubicin</i> (Cubist)	Daptomycin	Hospira, Teva ^{f,69}	June 2016 ¹⁹
<i>Nuvigil</i> (Teva)	Armodafinil	Actavis, Apotex, Breckenridge, Lupin, Mylan, Teva	June 2016 ³¹
<i>Zegerid/Zegerid OTC</i> (Salix)	Omeprazole/Sodium bicarbonate capsule and oral suspension	Par (capsule), Perrigo (capsule)	July 2016 ²⁴
<i>Ziana</i> (Medicis)	Clindamycin phosphate 1.2%/ Tretinoin 0.025%	Actavis	July 2016 ²
<i>Tygacil</i> (Wyeth)	Tigecycline injection	Sandoz	4 th quarter 2016 ¹¹³
<i>Azor</i> (Daiichi Sankyo)	Olmesartan/Amlodipine	Torrent	October 2016
<i>Benicar/Benicar HCT</i> (Daiichi Sankyo)	Olmesartan/Olmesartan HCTZ	<u>Olmesartan</u> : Mylan, Sandoz, Teva <u>Olmesartan HCTZ</u> : Mylan, Teva	October 2016 ²⁴
<i>Seroquel XR</i> (AstraZeneca)	Quetiapine extended-release tablet	Accord, Handa, Lupin, ^{f,43} Mylan, Osmotica, ^{f,53} Torrent ^{f,53}	November 2016 ⁷⁴
<i>Kaletra</i> (Abbott)	Lopinavir/Ritonavir	<u>Tablet</u> : Aurobindo, Cipla, Hetero, Matrix, Mylan <u>Oral solution</u> : Cipla	December 2016 ^{9,36}

Brand ^a (Manufacturer)	Generic Name	Generic Manufacturer(s) ^{b,1}	Anticipated Availability ^c
<i>ProAir HFA</i> (Teva)	Albuterol	Perrigo, ^{f,34} Catalent ^{f,34}	December 2016 ³⁴
<i>Relpax</i> (Pfizer)	Eletriptan	Apotex, Teva	December 2016 ⁹⁷
<i>Aggrenox</i> (Boehringer Ingelheim)	Aspirin/Dipyridamole	Barr	January 2017 (note: authorized generics now available)
<i>Revatio</i> (Pfizer)	Sildenafil injection	Aurobindo	January 2017
<i>Azilect</i> (Teva)	Rasagiline mesylate tablet	Actavis, ^{f,30} Alkem, Apotex, Mylan, Orchid, ^{f,30} Sandoz ^{f,30}	February 2017 ³⁰
<i>Vytorin</i> (Merck)	Ezetimibe/Simvastatin	Mylan	April 2017 ²⁸
<i>Zetia</i> (Merck)	Ezetimibe	Mylan	April 2017 ²⁸
<i>Strattera</i> (Lilly)	Atomoxetine	Actavis, ^{f,29} Apotex, Aurobindo, Dr. Reddy's, Glenmark, Mylan, Sandoz, Sun, Teva ^{f,29}	May 2017
<i>Metozolv</i> (Salix)	Metoclopramide orally disintegrating tablet	Novel	July 2017
<i>Reyataz</i> (Bristol-Myers Squibb)	Atazanavir	Aurobindo, Emcure, Matrix, Teva	July 2017 ⁵²
<i>Nasonex</i> (Merck)	Mometasone	Apotex, ^{h,111} Teva ^{h,96}	October 2017 ⁹⁶
<i>Sustiva</i> (Bristol-Myers Squibb)	Efavirenz	<u>Tablet</u> : Aurobindo, Cipla, Emcure, Hetero, Macleods, Matrix, Micro Labs, Par, Strides Arcolab <u>Capsule</u> : Aurobindo, Cipla, Micro Labs	December 2017 ²⁴
<i>Viagra</i> (Pfizer)	Sildenafil	Actavis, Amneal, Apotex, Aurobindo, Dr. Reddy's, Hetero, Macleods, Mylan, Teva	December 2017 ^{91,92}

Brand ^a (Manufacturer)	Generic Name	Generic Manufacturer(s) ^{b,1}	Anticipated Availability ^c
<i>Viread</i> (Gilead)	Tenofovir disoproxil fumarate	Aurobindo, Cipla, InvaGen, Lupin, Macleods, Matrix, Strides Arcolab, Teva	December 2017 ⁸
<i>Treximet</i> (Pozen)	Sumatriptan/Naproxen	Alphapharm, ^{f,102} Dr. Reddy's, Mylan, Par, Teva ^{f,102}	February 2018 ¹⁰²
<i>Sensipar</i> (Amgen)	Cinacalcet tablet	Teva	March 2018 ⁵¹
<i>Acanya</i> (Valeant)	Benzoyl peroxide/Clindamycin phosphate	Actavis	July 2018 ⁸⁷
<i>Atripla</i> (Gilead)	Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate	Aurobindo, Cipla, Emcure, Hetero, Macleods, Matrix, Teva	August 2018 ^{e,68}
<i>Aloxi</i> (Eisai)	Palonosetron injection	Dr. Reddy's, Sandoz, Teva	September 2018 ⁷⁸
<i>Fentora</i> (Cephalon)	Fentanyl citrate buccal/sublingual tablet	Actavis, ^{f,72} Teva, ^{f,56} Impax ^{f,57}	October 2018 ⁵⁶
<i>Levitra</i> (GlaxoSmithKline)	Vardenafil tablet	Macleods, Teva	October 2018 ¹⁰
<i>Staxyn</i> (Bayer)	Vardenafil orally disintegrating tablet	Actavis, Par ^{h,40}	October 2018 ^{d,40}
<i>Vesicare</i> (Astellas)	Solifenacin succinate	Actavis, Teva	October 2018 ²⁰
<i>Fortesta</i> (Endo)	Testosterone gel	Actavis	November 2018 ^{d,65}
<i>Lyrica</i> (Pfizer)	Pregabalin	<u>Capsule:</u> Actavis, Alembic, Apotex, Lupin, Mylan, Sandoz, Teva, Wockhardt <u>Oral solution:</u> Apotex, Lupin	December 2018 ⁵⁰
<i>Exelon</i> (Novartis)	Rivastigmine transdermal patch	Alvogen, Actavis, ^{h,66} Noven ^{h,64}	January 2019 ^d
<i>Ranexa</i> (Gilead)	Ranolazine	Lupin	February 2019 ⁸¹

Brand^a (Manufacturer)	Generic Name	Generic Manufacturer(s)^{b,1}	Anticipated Availability^c
<i>AzaSite</i> (InSite Vision)	Azithromycin 1% ophthalmic solution	Mylan, ^{h,16} Sandoz	March 2019 ^{d,16}
<i>Emend</i> (Merck)	Fosoprepitant injection	Accord, ^{h,35} Sandoz	March 2019 ^{d,35}
<i>Tarceva</i> (OSI)	Erlotinib tablet	Mylan	May 2019 ⁷³
<i>Uloric</i> (Takeda)	Febuxostat	Mylan, ^{h,89} Roxane, ^{h,106}	June 2019 ^{d,106}
<i>Factive</i> (Cornerstone)	Gemifloxacin tablet	Orchid	September 2019 ^{d,42}
<i>Prezista</i> (Janssen)	Darunavir tablet	Hetero, Lupin, Mylan, Teva	December 2019 ^{d,79}
<i>Silenor</i> (Somaxon)	Doxepin	Actavis, Mylan, Par, Zydus	January 2020 ³⁹
<i>Vigamox</i> (Alcon)	Moxifloxacin ophthalmic	Actavis, Akorn, Apotex, Lupin, Teva	March 2020 ^{d,6}
<i>Safyral</i> (Bayer)	Drospirenone/Ethinyl estradiol/Levomefolate calcium	Actavis	April 2020 ^{d,46}
<i>Chantix</i> (Pfizer)	Varenicline	Apotex, Mylan, Teva	May 2020 ^{d,49}
<i>Dexilant</i> (Takeda)	Dexlansoprazole	Par, TWI ^{f,93}	June 2020 ¹⁰⁴
<i>Lialda</i> (Shire)	Mesalamine delayed-release tablet	Zydus ^{h,76}	June 2020 ^d
<i>Lescol XL</i> (Novartis)	Fluvastatin extended-release	Mylan, Par, Teva	October 2020 ^{d,42}
<i>Adcirca</i> (Lilly)	Tadalafil	Synthon	November 2020 ^{d,18}
<i>Sutent</i> (Pfizer)	Sunitinib	Mylan	February 2021
<i>Absorica</i> (Ranbaxy)	Isotretinoin	Actavis ^{h,88}	September 2021 ^d

Brand ^a (Manufacturer)	Generic Name	Generic Manufacturer(s) ^{b,1}	Anticipated Availability ^c
<i>Bystolic</i> (Forest)	Nebivolol	Actavis, ^{f,67} Alkem, ^{f,67} Amerigen, ^{f,67} Glenmark, ^{f,63} Hetero, ^{f,67} Indchemie, ^{f,67} Torrent ^{f,67}	September 2021 ⁶³
<i>Emtriva</i> (Gilead)	Emtricitabine	Aurobindo, Cipla, Matrix	September 2021 ^{d,4}
<i>Truvada</i> (Gilead)	Emtricitabine/Tenofovir disoproxil fumarate	Aurobindo, Cipla, Hetero, Matrix, Strides Arcolab, Teva	September 2021 ^{d,21}
<i>Pristiq</i> (Wyeth)	Desvenlafaxine succinate extended-release tablet	Actavis, ^{h,33} Alembic, Achen, ^{h,33} Apotex, ^{h,33} Breckenridge, ^{h,33} Mylan, Lupin, Roxane, ^{h,33} Sandoz, Teva, ^{h,33} Wockhardt, ^{h,33} Zydus ^{h,33}	March 2022 ^{d,33}
<i>Vimpat</i> (UCB)	Lacosamide	<u>Tablet:</u> Accord, Actavis, Alembic, Amneal, Aurobindo <u>Oral solution:</u> Amneal, Apotex	March 2022 ^{d,5}
<i>Alimta</i> (Lilly)	Pemetrexed	Hospira	May 2022
<i>Vimovo</i> (AstraZeneca)	Naproxen/Esomeprazole magnesium delayed-release tablet	Actavis, ^{h,77} Anchen, ^{h,77} Dr. Reddy's, Lupin, ^{h,77} Mylan ^{h,77}	May 2022 ^{d,77}
<i>Januvia</i> (Merck)	Sitagliptin	Actavis, Apotex, Mylan, Sandoz, Sun, Teva	July 2022 ^{d,42,48}
<i>Toviaz</i> (Pfizer)	Fesoterodine extended-release tablet	Actavis, Accord, ^{h,108} Alembic, Alkem, ^{h,108} Amneal, Amerigen, Cadila, ^{h,108} Impax, ^{h,108} Lupin, Sandoz, Sun, Wockhardt, ^{h,82} Zydus ^{h,108}	July 2022 ^{d,82}
<i>Selzentry</i> (Pfizer)	Maraviroc	Hetero, Sandoz	November 2022 ^{d,42}
<i>Xyrem</i> (Jazz)	Sodium oxybate	Amneal, ^{h,7} Par, ^{h,7} Roxane ^{h,7}	December 2022 ^{d,7}
<i>Banzel</i> (Eisai)	Rufinamide	Glenmark, Hetero, ^{h,80} Lupin, ^{h,80} Mylan, Roxane	May 2023 ^{d,80}

Brand ^a (Manufacturer)	Generic Name	Generic Manufacturer(s) ^{b,1}	Anticipated Availability ^c
Vyvanse (Shire)	Lisdexamfetamine	Amneal, Mylan, Roxane, Sandoz	June 2023 ^{d,55}
Gralise (Depomed)	Gabapentin	Actavis, Incepta, ^{f,98} Zydus ^{f,98}	January 2024 ^{62,98}
Pataday (Alcon)	Olopatadine 0.2% ophthalmic solution	Actavis, Apotex, Teva, Wockhardt ^{h,100}	May 2024 ^{d,100,101}
Norvir (Ritonavir)	Ritonavir 100 mg tablet	Cipla, Mylan, ^{h,25} Hetero, ^{h,25} Roxane	February 2025 ^{d,25}
Nucynta (Janssen)	Tapentadol tablet	Actavis, Roxane	June 2025 ^{d,42}
Natazia (Bayer)	Dienogest/estradiol valerate	Actavis, ^{h,32} Lupin ^{h,61}	May 2026 ^{d,32,61}
Aplenzin (Biovail)	Bupropion hydrobromide extended- release tablet	Actavis, Paddock ^{h,83}	June 2026 ^d
Nuedexta (Avanir)	Dextromethorphan/Quinidine	Par, Sandoz, ^{f,103} Wockhardt ^{f,85}	July 2026 ^{85,103}
AndroGel 1.62% (AbbVie)	Testosterone	Perrigo ^{h,58}	October 2026 ^d
Solodyn (Medicis)	Minocycline extended-release tablet 55 mg, 65 mg, 80 mg, 105 mg, 115 mg	Aurobindo, Mylan, Sandoz, Sun, Teva	March 2027 ^{d,42}
Ampyra (Acorda)	Dalfampridine	Accord, ^{h,75} Actavis, ^{h,75} Aurobindo, ^{h,75} Roxane, ^{h,75} Alkem, ^{h,75} Mylan ^{h,75}	May 2027 ^{d,75}
Lumigan (Allergan)	Bimatoprost ophthalmic solution 0.01%	Apotex, Sandoz	June 2027
Axiron (Eli Lilly)	Testosterone transdermal solution	Actavis, Perrigo ^{h,112}	September 2027 ^d
Oracea (Galderma)	Doxycycline	Lupin, Mylan	December 2027 ^{d,110}
Janumet (Merck)	Sitagliptin/Metformin	Anchen, Apotex, Sandoz	July 2028 ^{d,42}

Brand^a (Manufacturer)	Generic Name	Generic Manufacturer(s)^{b,1}	Anticipated Availability^c
<i>Nucynta ER</i> (Janssen)	Tapentadol extended-release tablet	Actavis	September 2028 ^{d,42}
<i>Onglyza</i> (Bristol-Myers Squibb)	Saxagliptin	Actavis ^{h,99}	November 2028 ^{d,99}
<i>Lo Loestrin Fe</i> (Actavis)	Ethinyl estradiol/Norethindrone acetate/Ferrous fumarate	Actavis, ^{h,11} Amneal, ^{h,95} Lupin ^{f,95}	February 2029 ^{d,95}
<i>Isentress</i> (Merck)	Raltegravir tablet	Hetero	March 2029 ^{d,42}
<i>Remodulin</i> (United Therapeutics)	Treprostinil injection	Sandoz	March 2029 ^{d,42}
<i>Moxeza</i> (Alcon)	Moxifloxacin ophthalmic solution	Lupin	May 2029 ^{d,42}
<i>Qsymia</i> (Vivus)	Phentermine/Topiramate extended-release capsule	Actavis ^{h,41}	June 2029 ^{d,41}
<i>Intermezzo</i> (Purdue)	Zolpidem sublingual tablet	Novel	August 2029 ^{d,42}
<i>Savella</i> (Cypress)	Milnacipran	Amneal, Mylan	September 2029 ^{d,14}
<i>Travatan Z</i> (Alcon)	Travoprost 0.004% ophthalmic solution	Apotex	October 2029 ^{d,42}
<i>Contrave</i> (Orexigen)	Bupropion/Naloxone sustained release tablet	Actavis ^{h,114}	February 2030 ^d
<i>Suboxone</i> (Reckitt Benckiser)	Buprenorphine/Naloxone sublingual film	Actavis ^{h,86}	March 2030 ^{d,86}
<i>Copaxone</i> (Teva)	Glatiramer 40 mg/mL	Dr. Reddy's, ^{h,94} Mylan, ^{h,70} Momenta, ^{h,70} Sandoz ^{h,70}	August 2030 ^d
<i>Jevtana</i> (Sanofi Aventis)	Cabazitaxel	Accord, Actavis, Breckenridge ^{h,54}	October 2030 ^d
<i>Zubsolv</i> (Orexo)	Buprenorphine/Naloxone sublingual tablet	Actavis ^{h,84}	September 2032 ^d
<i>Advicor</i> (Abbott)	Lovastatin/Niacin	Teva ^{f,107}	Uncertain ⁹⁷

Brand^a (Manufacturer)	Generic Name	Generic Manufacturer(s)^{b,1}	Anticipated Availability^c
<i>Alocril</i> (Allergan)	Nedocromil ophthalmic	Akorn	Uncertain ^g
<i>Atralin</i> (Coria)	Tretinoin gel 0.05%	Spear	Uncertain ^g
<i>Avandamet</i> (SB Pharmco)	Rosiglitazone/Metformin (brand discontinued)	Teva	Uncertain ²⁷
<i>Avandaryl</i> (SB Pharmco)	Rosiglitazone/Glimepiride (brand discontinued)	Teva	Uncertain ²⁷
<i>Avandia</i> (SB Pharmco)	Rosiglitazone	Actavis, Dr. Reddy's, Mylan, Roxane, Sandoz, Teva, Westward (Hikma)	Uncertain ²⁷
<i>CellCept</i> (Roche Palo)	Mycophenolate mofetil hydrochloride injection	Bedford Labs	Uncertain ^g
<i>CellCept</i> (Roche Palo)	Mycophenolate mofetil oral suspension	Alkem	Uncertain ^g
<i>Exalgo</i> (Mallinckrodt)	Hydromorphone extended-release tablet 32 mg	Actavis ^{f,3}	Uncertain ^g
<i>Exelon</i> (Novartis)	Rivastigmine oral solution	Ranbaxy	Uncertain ^g
<i>Glyset</i> (Pharmacia & Upjohn)	Miglitol tablets	Orient	Uncertain ^g
<i>Invega</i> (Janssen)	Paliperidone extended-release tablet	Actavis	Uncertain ^g
<i>Latisse</i> (Allergan)	Bimatoprost 0.03%	Apotex	Uncertain ⁴⁵
<i>Oxytrol</i> (Actavis)	Oxybutynin transdermal patch	Teva	Uncertain ^{37,44}
<i>Prandimet</i> (Novo Nordisk)	Repaglinide/metformin tablet	Lupin	Uncertain ^g
<i>Renagel</i> (Genzyme)	Sevelamer hydrochloride (oral suspension)	Impax ^{f,15}	Uncertain

Brand ^a (Manufacturer)	Generic Name	Generic Manufacturer(s) ^{b,1}	Anticipated Availability ^c
<i>Renvela</i> (Genzyme)	Sevelamer carbonate (oral suspension)	Impax ^{f,15}	Uncertain
<i>Rezira</i> (Hawthorn)	Hydrocodone/pseudoephedrine oral solution	Tris Pharma, Paddock (Perrigo)	Uncertain ^g
<i>Sarafem</i> (Warner Chilcott)	Fluoxetine tablet	Teva	Uncertain ^g
<i>Welchol</i> (Daiichi Sankyo)	Colesevelam tablet and oral suspension	Impax, ^{f,22} Actavis, ^{h,23,71} Glenmark ^{f,59}	Uncertain ^{22,59}
<i>Zyvox</i> (Pfizer)	Linezolid oral suspension	Roxane	Uncertain ^{g,47}

- a. This list is not all-inclusive.
- b. Current through August 2015. These are manufacturers with either approval or tentative approval to market the generic version of the drug unless otherwise noted. For drugs already available, manufacturers with tentative approval are not listed.
- c. Generic availability is subject to change as a result of litigations and patent exclusivities.
- d. Patent challenge filed; availability may be sooner than patent expiration date.
- e. Generic manufacturer has settled patent litigation with the brand manufacturer. Generic availability may be sooner than patent expiration date.
- f. Generic manufacturer has not received approval or tentative approval from the FDA, but has settled patent litigation with the brand manufacturer.
- g. Patents have expired; however, generics are not yet available.
- h. Generic manufacturer has not received approval or tentative approval from the FDA, but has filed patent challenge.
- i. A biosimilar is not a generic. Biosimilars and their reference product are complex biologic medicines that originate in living organisms. A biosimilar is not the exact duplicate of the reference biologic, but is very similar and is expected to have the same efficacy and safety for its approved indications.⁶⁰

Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication.

Project Leader in preparation of this PL Detail-Document: Melanie Cupp, Pharm.D., BCPS

References

1. Drugs@FDA. FDA approved drug products. <http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm>. (Accessed August 31, 2015).
2. Anon. Actavis reaches agreements with Valeant to launch generic versions of *Ziana* and *Zyclara*. April 10, 2013. <http://ir.valeant.com/investor-relations/news-releases/news-release-details/2013/Actavis-Reaches-Agreements-with-Valeant-to-Launch-Generic-Versions-of-Ziana-and-Zyclara/default.aspx>. (Accessed August 31, 2015).
3. Liss S. Mallinckrodt settles patent litigation with Actavis. February 14, 2013. <http://www.bizjournals.com/stlouis/blog/2013/02/mallinckrodt-settles-patent-litigation.html>. (Accessed August 31, 2015).
4. Leonhardt M. Gilead hits Cipla with patent suit over HIV drug *Emtriva*. August 21, 2012. <http://www.law360.com/articles/371648/gilead-hits-cipla-with-patent-suit-over-hiv-drug-emtriva>. (Accessed August 25, 2015).
5. Anon. UCB files *Vimpat* patent claims against 15 companies. July 23, 2013. http://www.pmlive.com/pharma_news/ucb_files_vimpat_at_patent_claims_against_15_companies_491658. (Accessed August 26, 2015).
6. Anon. Watson Pharma confirms *Vigamox* patent challenge - quick facts. April 8, 2011. <http://www.rttnews.com/1594272/watson-pharma-confirms-vigamox-patent-challenge-quick-facts.aspx>. (Accessed August 26, 2015).
7. Anon. Amneal, Par, and Roxane challenge distribution patent for *Xyrem* under AIA covered business method review. June 24, 2015. <http://www.bigmoleculewatch.com/2015/06/24/amneal-par-and-roxane-challenge-distribution-patent-for-xyrem-under-aia-covered-business-method-review/>. (Accessed August 25, 2015).
8. Anon. Gilead, Teva reach settlement in *Viread* patent lawsuit. February 19, 2013. <http://www.reuters.com/article/2013/02/20/us-gilead-teva-idUSBRE91J05920130220>. (Accessed August 24, 2015).
9. Anon. Abbott's pipeline is crucial in advance of 2016 patent cliff. May 30, 2012. <http://www.forbes.com/sites/greatspeculations/2012/05/30/abbotts-pipeline-is-crucial-in-advance-of-2016-patent-cliff/>. (Accessed August 23, 2015).
10. Chutchian M. Teva, Bayer settle dispute over *Levitra* patents. November 21, 2011. <http://www.law360.com/articles/287554/teva-bayer-settle-dispute-over-levitra-patents>. (Accessed September 1, 2015).
11. Anon. Watson confirms *Lo Loestrin Fe* Patent challenge. <http://www.allergan.com/news/news/thomson-reuters/watson-confirms-lo-loestrin-fe-patent-challenge>. (Accessed August 29, 2015).
12. Dearment A. Impax Labs to market generic or authorized generic version of *OxyContin* under deal with Purdue Pharma. December 3, 2013. <http://drugstorenews.com/article/impax-labs-market-generic-or-authorized-generic-version-oxycontin-under-deal-purdue-pharma>. (Accessed August 31, 2015).
13. Vinluan F. GSK sues to block generic BPH drugs from Mylan, Impax. September 12, 2011. <http://medcitynews.com/2011/09/gsk-sues-to-block-generic-bph-drugs-from-mylan-impax/>. (Accessed August 21, 2015).
14. Anon. Mylan confirms first-to-file patent challenge relating to *Savella*. September 25, 2013. <http://www.prnewswire.com/news-releases/mylan-confirms-first-to-file-patent-challenge-relating-to-savella-225175972.html>. (Accessed August 29, 2015).
15. Anon. Impax Laboratories announces settlement of litigation relating to *Renvela* and *Renagel*. September 4, 2012. <http://investors.impaxlabs.com/Media-Center/Press-Releases/Press-Release-Details/2012/Impax-Laboratories-Announces-Settlement-of-Litigation-Relating-to-REVELA-and-RENAGEL1130841/default.aspx>. (Accessed August 31, 2015).
16. Anon. US court upholds all *AzaSite* patents in patent lawsuit against Sandoz. October 9, 2013. <http://pharmabiz.com/PrintArticle.aspx?aid=78081>. (Accessed August 25, 2015).
17. Anon. Santarus and Depomed announce settlement with Lupin of *Glumetza* patent litigation. February 22, 2012. <http://www.reuters.com/article/2012/02/22/idUS212258+22-Feb-2012+BW20120222>. (Accessed August 22, 2015).
18. Anon. Lilly sues to block generic of *Adcirca* lung treatment. March 17, 2010. <http://www.ibj.com/articles/18745-lilly-sues-to-block-generic-of-adcirca-lung-treatment>. (Accessed August 25, 2015).
19. Pierson B. Court rules Hospira can launch generic *Cubicin* in 2016. December 8, 2014. <http://www.reuters.com/article/2014/12/08/us-health-cubist-pharm-idUSKBN0JM2HQ20141208>. (August 22, 2015).
20. Anon. Astellas and Teva reached a settlement agreement on *Vesicare* patent case. June 28, 2010. <http://www.astellas.com/en/corporate/news/detail/astellas-and-teva-reached-a-se.html>. (Accessed August 25, 2015).
21. McKenzie L. Gilead sues Teva over *Truvada* ANDA. December 16, 2008. <http://www.law360.com/articles/80464/gilead-sues-teva-over-truvada-anda>. (Accessed August 26, 2015).
22. Impax settles *WeiChol* patent lawsuit with Daiichi Sankyo, Genzyme-update. June 30, 2011.

More . . .

- <http://www.rttnews.com/1657371/impax-settles-welchol-patent-lawsuit-with-daiichi-sankyo-genzyme-update.aspx>. (Accessed August 21 2015).
23. Anon. Watson confirms *Welchol* patent challenge. April 20, 2011. [http://actavis.com/news/news/thomson-reuters/watson-confirms-welchol\(r\)-patent-challenge](http://actavis.com/news/news/thomson-reuters/watson-confirms-welchol(r)-patent-challenge). (Accessed August 20, 2015).
 24. Corporate Pharmacy Services. Upcoming generic drugs. http://corporatepharmacy.com/page/upcoming_generic_drugs. (Accessed August 21, 2015).
 25. Teichert E. AbbVie hits Roxane with patent suit over *Norvir*. July 19, 2013. <http://www.law360.com/articles/458511/abbvie-hits-roxane-with-patent-suit-over-norvir>. (Accessed August 28, 2015).
 26. George J. Settlement reached in *Crestor* patent lawsuit. Philadelphia Business Journal. March 25, 2013. <http://www.bizjournals.com/philadelphia/news/2013/03/25/settlement-reached-in-crestor-patent.html>. (Accessed August 22, 2015).
 27. Press release: Teva announces settlement of generic *Avandia*, *Avandamet*, and *Avandaryl* litigation with GlaxoSmithKline. <http://www.fiercebitech.com/press-releases/press-release-teva-announces-settlement-generic-avandia-avandamet-and-avandaryl-litig>. (Accessed August 31, 2015).
 28. Merck wins U.S. *Zetia* (ezetimibe)/*Vytorin* (ezetimibe/simvastatin) patent infringement lawsuit. April 27, 2012. <http://www.mercknewsroom.com/press-release/corporate-news/merck-wins-us-zetia-ezetimibe-vytorin-ezetimibesimvastatin-patent-infri> (Accessed August 23, 2015).
 29. Decker S. Lilly wins appeals court ruling in *Strattera* patent case. July 29, 2011. <http://www.bloomberg.com/news/2011-07-29/lilly-wins-appeals-court-ruling-in-strattera-patent-case-1.html>. (Accessed August 24, 2015).
 30. Anon. Teva announces favorable court ruling in *Azilect* patent infringement litigation. September 23, 2013. <http://www.pharmpro.com/news/2013/09/teva-announces-favorable-court-ruling-azilect%20AE-patent-infringement-litigation>. (Accessed August 22, 2015).
 31. Dearment A. Mylan to launch generic version of *Nuvigil* in 2016. April 30, 2012. <http://www.drugstorenews.com/article/mylan-launch-generic-version-nuvigil-2016>. (Accessed August 22, 2015).
 32. United States District Court for the District of Delaware. Bayer Pharma AG, Bayer Intellectual Property GMBH, and Bayer Healthcare Pharmaceuticals Inc. vs Watson Pharmaceuticals, Inc. and Watson Laboratories, Inc. Complaint. December 18, 2012. <http://patentdocs.typepad.com/files/bayer-v-watson-1.pdf>. (Accessed August 26, 2015).
 33. Donahue B. Pfizer sues 11 rivals to defend *Pristiq* patent. June 25, 2012. <http://www.law360.com/articles/353660/pfizer-sues-11-rivals-to-defend-pristiq-patent>. (Accessed August 28, 2015).
 34. Alexander A. Teva reaches settlement in *ProAir HFA* patent case. June 20, 2014. <http://www.drugstorenews.com/article/teva-reaches-settlement-proair-hfa-patent-case>. (Accessed August 23, 2015).
 35. Sarfo A. Sandoz, Intas can't ditch Merck's suit over generic *Emend*. February 15, 2013. <http://www.law360.com/articles/415840/sandoz-intas-can-t-ditch-merck-s-suit-over-generic-emend>. (Accessed August 25, 2015).
 36. United States District Court for the Northern District of Illinois. Abbott Laboratories vs Matrix Laboratories, Inc., Matrix Laboratories, LTD, Mylan Inc. Memorandum in support of defendants' motion to stay. May 22, 2009. <http://www.fdalawblog.net/files/matrix---motion-to-stay.pdf>. (Accessed August 23, 2015).
 37. Anonymous. Watson and Barr settle lawsuit over *Oxytrol*. October 29, 2009. <http://www.pharmaceuticalonline.com/doc/watson-and-barr-settle-lawsuit-over-oxytrol-0001>. (Accessed August 21, 2015).
 38. Howard S. Celgene, Novartis settle with Barr over generic *Ritalin*. April 26, 2010. <http://www.law360.com/articles/164315/celgene-novartis-settle-with-barr-over-generic-ritalin>. (Accessed August 25, 2015).
 39. Anon. Somaxon Pharmaceuticals announces settlement of *Silenor* patent litigation with Actavis. February 5, 2013. <http://www.globenewswire.com/news-release/2013/02/05/521096/10020662/en/Somaxon-Pharmaceuticals-Announces-Settlement-of-Silenor-Patent-Litigation-With-Actavis.html>. (Accessed August 25, 2015).
 40. Wilson D. Bayer hits Par with patent suit over *Staxyn* generic. May 15, 2013. <http://www.law360.com/articles/441636/bayer-hits-par-with-patent-suit-over-staxyn-generic>. (Accessed August 29, 2015).
 41. Vivus files lawsuit against Actavis for infringement of *Qsymia* patents. June 12, 2014. <http://finance.yahoo.com/news/vivus-files-lawsuit-against-actavis-203248525.html>. August 29, 2015. (Accessed August 29, 2015).
 42. Paragraph IV patent certifications. August 18, 2015. <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM293268.pdf>. (Accessed August 26, 2015).
 43. Anon. AstraZeneca settles *Seroquel XR* case against Lupin. April 24, 2013. <http://www.fdanews.com/newsletter/article?issueId=16755&articleId=154996>. (Accessed August 22, 2015).

More . . .

44. Coe E. Watson settles with Barr over *Oxytrol*. October 28, 2009. <http://www.law360.com/articles/130896/watson-settles-with-barr-over-oxytrol>. (Accessed April 17, 2015).
45. Decker S. Allergan's patents on eyelash growth drug invalid: court. June 10, 2014. <http://www.bloomberg.com/news/2014-06-10/allergan-s-patents-on-eyelash-growth-drug-invalid-court.html>. (Accessed August 31, 2015).
46. Anon. Actavis confirms generic *Safyral* patent challenge. June 5, 2013. <http://www.pnewswire.com/news-releases/actavis-confirms-generic-safyral-patent-challenge-210297921.html>. (Accessed August 25, 2015).
47. FDA. Linezolid oral suspension ANDA approval letter (Roxane Laboratories, Inc). June 3, 2015. http://www.accessdata.fda.gov/drugsatfda_docs/appl_etter/2015/200068Orig1s000ltr.pdf. (Accessed August 21, 2015).
48. Mukherjee R. US nod to Sun for Merck drug sale raises eyebrows. April 16, 2013. <http://timesofindia.indiatimes.com/business/india-business/US-nod-to-Sun-for-Merck-drug-sale-raises-eyebrows/articleshow/19571824.cms>. (Accessed August 27, 2015).
49. Anon. Lawsuit over generic *Chantix* version filed by Pfizer. September 3, 2010. <http://www.aboutlawsuits.com/generic-chantix-lawsuit-filed-by-pfizer-12564/>. (Accessed August 27, 2015).
50. Decker S. Pfizer wins ruling to block generic *Lyrice* until 2018. February 6, 2014. <http://www.bloomberg.com/news/2014-02-06/pfizer-wins-ruling-to-block-generic-lyrice-until-2018.html>. (Accessed August 25, 2015).
51. Decker S. Amgen wins ruling blocking Teva's generic *Sensipar*. January 7, 2011. <http://www.bloomberg.com/news/2011-01-07/amgen-wins-ruling-against-teva-in-generic-sensipar-fight.html>. (Accessed August 24, 2015).
52. Loftus P. Bristol settles patent dispute with Teva over *Reyataz* HIV drug. October 27, 2011. <http://online.wsj.com/news/articles/SB10001424052970203554104577001490166083700>. (Accessed August 24, 2015).
53. Baynes T. U.S. appeals court finds Astra's *Seroquel XR* patent infringed. February 14, 2013. <http://www.reuters.com/article/2013/02/15/us-astrazeneca-seroquel-idUSBRE91E02D20130215>. (Accessed August 22, 2015).
54. Anon. Breckenridge Pharmaceutical, Inc. announces paragraph IV ANDA litigation with Sanofi for its ANDA cabazitaxel solution; IV (infusion)(*Jevtana*). February 11, 2015. <http://www.pnewswire.com/news-releases/breckenridge-pharmaceutical-inc-announces-paragraph-iv-anda-litigation-with-sanofi-for-its-anda-cabazitaxel-solution-iv-infusion-jevtana-300034726.html>. (Accessed August 31, 2015).
55. Hirschler B. Patent win helps Shire as AbbVie plots next bid move. June 25, 2014. <http://www.reuters.com/article/2014/06/25/us-shire-vyvanse-idUSKBN0F00IV20140625>. (Accessed September 1, 2015).
56. Anon. Upheld *Fentora* patent staves off generic. March 28, 2011. <http://www.ddmag.com/news/2011/03/upheld-fentora-patent-staves-generic>. (Accessed August 25, 2015).
57. Anon. Cephalon, Impax settle suit over *Fentora* generic. July 23, 2013. <http://maxval-ip.blogspot.com/2013/07/cephalon-impax-settle-suit-over-fentora.html>. (Accessed August 25, 2015).
58. Anon. Perrigo confirms first to file patent challenge for generic version of testosterone gel 1.62%. February 19, 2013. <http://perrigo.investorroom.com/2013-02-19-Perrigo-Confirms-First-to-File-Patent-Challenge-for-Generic-Version-of-Testosterone-Gel-1.62>. (Accessed August 27, 2015).
59. Anon. Glenmark announces settlement of litigation with Daiichi Sankyo & Genzyme for colesevelam hydrochloride. July 4, 2011. http://www.glenmarkpharma.com/GLN_NWS/pdf/Colesevelam_HCL.PDF. (Accessed August 21, 2015).
60. FDA. Biosimilars: more treatment options are on the way. March 6, 2015. <http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm436399.htm>. (Accessed August 31, 2015).
61. Sarfo A. Bayer targets Lupin over generic *Natazia*. November 29, 2012. <http://www.law360.com/articles/397373/bayer-targets-lupin-over-generic-natazia>. (Accessed August 26, 2015).
62. Anon. Depomed, Actavis settle *Gralise* ANDA patent infringement litigation. April 15, 2015. <http://www.pharmabiz.com/NewsDetails.aspx?aid=87759&sid=2>. (Accessed August 26, 2015).
63. Anon. Forest enters into fifth *Bystolic* settlement. January 23, 2013. <http://fdanews.com/newsletter/article?issueId=16486&articleId=152574>. (Accessed August 25, 2015).
64. James B. Novartis sues Noven to block generic dementia patch. April 3, 2013. <http://www.law360.com/articles/429980/novartis-sues-noven-to-block-generic-dementia-patch>. (Accessed August 25, 2015).
65. Anon. Actavis confirms generic *Fortesta* patent challenge. March 1, 2013. <http://www.pnewswire.com/news-releases/actavis-confirms-generic-fortesta-patent-challenge-194191101.html>. (Accessed August 25, 2015).
66. Actavis' (ACT) generic *Exelon* patch infringes two U.S. patents. June 19, 2014. <http://www.streetinsider.com/Corporate+News/Actavis+%28ACT%29+Generic+Exelon+Patch+Infringes+Two+U.S.+Patents/9597337.html>. (Accessed August 25, 2015).
67. Anon. Forest Laboratories announces settlement of *Bystolic* patent litigation. November 8, 2013. <http://processandproduction.pharmaceutical-business-review.com/news/forest-laboratories>

More . . .



- announces-settlement-of-bystolic-patent-litigation-081113. (Accessed August 25, 2015).
68. Wilson D. Teva settles with BMS, Merck over HIV drug generic plans. June 6, 2013. <http://www.law360.com/articles/448059/teva-settles-with-bms-merck-over-hiv-drug-generic-plans>. (Accessed August 25, 2015).
69. Anon. Update 1-Cubist's antibiotic gets generic threat from Hospira. February 9, 2012. <http://www.reuters.com/article/2012/02/09/cubistpharma-idUSL4E8D93XD20120209>. (Accessed August 22, 2015).
70. Anon. More generics companies targeting Teva's Copaxone 40 mg. September 8, 2014. <http://www.fdanews.com/articles/166954-more-generics-makers-targeting-tevas-copaxone-40-mg>. (Accessed August 29, 2015).
71. Anon. Watson confirms *Welchol* oral suspension patent challenge. January 25, 2011. <http://www.prnewswire.com/news-releases/Watson-confirms-welchol-oral-suspension-patent-challenge-114594049.html>. (Accessed August 21, 2015).
72. Decker S. Actavis wins patent appeal for generic to Teva's *Fentora*. February 14, 2013. <http://www.bloomberg.com/news/articles/2013-02-14/actavis-wins-appeal-over-two-patents-for-teva-s-fentora-drug-1->. (Accessed August 25, 2015).
73. United States District Court for the District of Delaware. OSI Pharmaceuticals, Inc., Pfizer, Inc., and Genentech Inc. vs Mylan Pharmaceuticals Inc. Opinion. May 1, 2012. http://www.ded.uscourts.gov/sites/default/files/opinions/slr/2012/may/09-185_1.pdf. (Accessed September 1, 2015).
74. Ugolik K. AstraZeneca, Handa settle *Seroquel* patent fight. September 29, 2011. <http://www.law360.com/articles/274826/astrazeneca-handa-settle-seroquel-patent-fight>. (Accessed August 22, 2015).
75. Anon. Acorda fighting six generic challenges to *Ampyra*. July 25, 2014. <http://www.fdanews.com/articles/166014-acorda-fighting-six-generic-challenges-to-ampyra>. (Accessed August 28, 2015).
76. Feeley J. Shire faces patent suit revival over *Lialda* colitis drug. February 28, 2014. <http://www.bloomberg.com/news/articles/2014-02-28/shire-faces-patent-suit-revival-over-lialda-colitis-drug>. (Accessed August 25, 2015).
77. Zagger Z. AstraZeneca sues 4 drugmakers to stop generic *Vimovo*. October 25, 2013. <http://www.law360.com/articles/483202/astrazeneca-sues-4-drugmakers-to-stop-generic-vimovo>. (Accessed April 24, 2015).
78. Anon. Helsinn reaches settlement agreement regarding patent dispute on *Aloxi*. January 12, 2015. <http://www.prnewswire.com/news-releases/helsinn-reaches-settlement-agreement-regarding-patent-dispute-on-aloxi-288224391.html>. (Accessed August 25, 2015).
79. Sarfo A. Lupin hit with suit over generic *Prezista*. July 2, 2013. <http://www.law360.com/articles/454515/lupin-hit-with-suit-over-generic-prezista>. (Accessed August 28, 2015).
80. Wilson D. Novartis, Eisai sue rivals over planned *Banzel* generics. July 25, 2013. <http://www.law360.com/articles/459945/novartis-eisai-sue-rivals-over-planned-banzel-generics>. (Accessed August 26, 2015).
81. Anon. Roche, Gilead end patent dispute with Lupin. August 15, 2013. http://ipprolifesciences.com/ipprolifesciencesnews/pharmaceuticalsarticle.php?article_id=87. (Accessed August 25, 2015).
82. Wilson D. Pfizer targets Wockhardt in generic *Toviaz* suit. August 5, 2013. <http://www.law360.com/articles/462536/pfizer-targets-wockhardt-in-generic-toviaz-suit>. (Accessed August 28, 2015).
83. Allison J. Biovail files 2nd suit over Watson's *Aplenzin* ANDA. April 19, 2010. <http://www.law360.com/articles/162795/biovail-files-2nd-suit-over-watson-s-aplenzin-anda>. (Accessed August 26, 2015).
84. Chavis R. Actavis confirms patent challenge surrounding generic *Zubsolv*. June 30, 2014. <http://www.drugstorenews.com/article/actavis-confirms-patent-challenge-surrounding-generic-zubsolv>. (Accessed August 29, 2015).
85. Anon. Avanir Pharmaceuticals announces settlement of *Nuedexta* patent litigation with Wockhardt. September 6, 2013. <http://www.prnewswire.com/news-releases/avanir-pharmaceuticals-announces-settlement-of-nuedexta-patent-litigation-with-wockhardt-222703741.html>. (Accessed August 26, 2015).
86. Dearment A. Actavis seeks approval for generic opioid-dependence drug. October 15, 2013. <http://drugstorenews.com/article/actavis-seeks-approval-generic-opioid-dependence-drug>. (Accessed August 29, 2015).
87. Johnsen M. Valeant grants Actavis license to market generic *Acanya* gel beginning July 1, 2018. May 12, 2014. <http://drugstorenews.com/article/valeant-grants-actavis-license-market-generic-acanya-gel-beginning-july-1-2018>. (Accessed April 20, 2015).
88. Dearment A. Actavis applies for approval of generic version of *Absorica*. October 31, 2013. <http://drugstorenews.com/article/actavis-applies-approval-generic-acne-drug>. (Accessed August 25, 2015).
89. Dearment A. Mylan files for approval of generic gout drug. November 1, 2013. <http://drugstorenews.com/article/mylan-files-approval-generic-gout-drug>. (Accessed August 30, 2015).
90. Anon. Warner Chilcott settles with Zydus over generic *Asacol HD*. December 11, 2013. <http://drugstorenews.com/article/warner-chilcott-settles-zydus-over-generic-asacol-hd>. (Accessed August 21, 2015).
91. Anon. Pfizer, Teva reach deal to allow generic *Viagra*. December 18, 2013. <http://www.law360.com/articles/454515/lupin-hit-with-suit-over-generic-prezista>. (Accessed August 28, 2015).

More . . .

- http://seattletimes.com/html/business/technology/202477168_apxpfizergenericviagra.html. (Accessed September 1, 2015).
92. Koppala AR. Mylan settles *Viagra* patent litigation with Pfizer. April 13, 2015. <http://www.reuters.com/article/2015/04/13/us-mylan-litigation-pfizer-idUSKBN0N423K20150413>. (Accessed April 14, 2015).
93. Anon. TWi announces settlement with Takeda on *Dexilant* litigation. April 27, 2015. <http://www.prnewswire.com/news-releases/twi-announces-settlement-with-takeda-on-dexilant-litigation-300072295.html>. (Accessed August 29, 2015.)
94. Koenig B. Dr. Reddy's files first paragraph IV ANDA against Teva's *Copaxone* 40 mg. August 15, 2014. <http://www.fdanews.com/articles/166376-dr-reddys-files-first-paragraph-iv-anda-against-tevas-40mg-copaxone?v=preview>. (Accessed August 29, 2015).
95. Anon. Actavis confirms U.S. District Court upholds *Lo Loestrin Fe* patent. January 17, 2014. <http://www.theflyonthewall.com/permalinks/entry.php/ACTid1948286/ACT-Actavis-confirms-US-District-Court-upholds-Lo-Loestrin-Fe-patent->. (Accessed August 25, 2015).
96. Anon. Teva's generic *Nasonex* bid is challenged by Merck. July 11, 2014. <http://www.fdanews.com/articles/165720-tevas-generic-nasonex-bid-is-challenged-by-merck>. (Accessed August 24, 2015).
97. Anon. Rx Outlook. 2nd Q 2014. http://catamaranrx.com/uploadedFiles/Documents/Clinical_Publications/Rx_Outlook/RxOutlook_Digest_Generic_Pipeline_Q2_2014.pdf. (Accessed August 22, 2015).
98. Anon. Depomed announces settlement with two *Gralise* ANDA filers. April 14, 2014. <http://www.biotechnologyevents.com/node/4855>. (Accessed August 26, 2015).
99. Anon. Actavis confirms generic *Onglyza* patent challenge. May 27, 2014. <http://www.prnewswire.com/news-releases/actavis-confirms-generic-onglyza-patent-challenge-260817921.html>. (Accessed August 29, 2015).
100. Anon. Alcon sues Wockhardt for patent infringement of *Pataday*. September 25, 2013. <http://www.iniplaw.org/2013/09/alcon-sues-wockhardt-for-paten.html>. (Accessed August 26, 2015).
101. Decker S. Novartis's Alcon sues Actavis to block copy of pink eye treatment. June 13, 2011. <http://www.bloomberg.com/news/2011-06-13/novartis-s-alcon-sues-watson-to-block-copy-of-pink-eye-treatment.html>. (Accessed August 25, 2015).
102. Anon. Pozen patents upheld in *Treximet* patent litigation. August 8, 2011. <http://www.businesswire.com/news/home/2011080805396/en/Pozen-Patents-Upheld-Treximet-Patent-Litigation#.U4XyBn7D-1s>. (Accessed August 24, 2015).
103. Anon. Avanir, Sandoz settle *Nuedexta* patent suit. August 14, 2013. <http://www.drugs.com/news/avanir-sandoz-settle-nuedexta-patent-suit-46708.html>. (Accessed August 27, 2015).
104. Lawson A. Takeda triumphs in suits to block generic *Dexilant*. November 4, 2013. <http://www.law360.com/articles/485773/takeda-triumphs-in-suits-to-block-generic-dexilant>. (Accessed August 29, 2015).
105. Alembic Pharma Q1FY16 earnings conference call. July 31, 2015. <http://www.alembic-india.com/upload/05Transcript-APL-Jul31-2015.pdf>. (Accessed August 21, 2015).
106. Anon. Roxane faces patent infringement suit over *Uloric* generic. February 19, 2014. <http://maxvalip.blogspot.com/2014/02/roxane-face-patent-infringement-suit.html>. (Accessed August 30, 2015).
107. Meland M. Kos, Barr settle *Niaspan* patent litigation with unusual deal. April 13, 2005. <http://www.law360.com/articles/3283/kos-barr-settle-niaspan-patent-litigation-with-unusual-deal>. (Accessed August 31, 2015).
108. Dugdale M. Pfizer seeks *Toviaz* protection. July 2, 2013. http://www.ipprolifesciences.com/ipprolifesciencesnews/article.php?article_id=17#.VUO9mpUtG1s. (Accessed August 28, 2015).
109. Press release. Boehringer Ingelheim. FDA grants tentative approval for Lilly and Boehringer Ingelheim's *Basaglar* (insulin glargine injection). August 18, 2014. http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/08-18-14-fda-grants-tentative-approval-lilly-boehringer-ingelheim-basaglar-insulin-glargine-injection.html. (Accessed August 31, 2015).
110. Lawson A. Step backwards for generic *Oracea*. Invalid patents are back. August 7, 2013. <http://rosacea-support.org/step-backwards-for-generic-oracea-invalid-patents-are-back.html>. (Accessed August 28, 2015).
111. Anon. Merck loses *Nasonex* patent lawsuit against Apotex in U.S. June 18, 2012. <http://pharmabiz.com/NewsDetails.aspx?aid=69616&sid=2>. (Accessed August 24, 2015).
112. Anon. Perrigo confirms patent challenge for generic version of *Axiron* topical solution. <http://www.prnewswire.com/news-releases/perrigo-confirms-patent-challenge-for-generic-version-of-axiron-topical-solution-209316141.html>. (Accessed September 1, 2015).
113. Kansas Department of Health and Environment. Caremark generic prospective pipeline summary-launch expected 2015 to 2016. July 17, 2015. <http://www.kdheks.gov/hcf/sehp/BenefitDescriptions/CVSCaremark/2015CaremarkGenericPipeline.pdf>. (Accessed August 20, 2015).
114. Anon. Orexigen announces receipt of paragraph IV certification notice. April 22, 2015. <http://www.prnewswire.com/news-releases/orexigen-announces-receipt-of-paragraph-iv-certification-notice-300070030.html>. (Accessed August 29, 2015).

More . . .

Cite this document as follows: *PL Detail-Document, Anticipated Availability of First-Time Generics. Pharmacist's Letter/Prescriber's Letter. September 2015.*

	<i>Evidence and Recommendations You Can Trust...</i>	
3120 West March Lane, Stockton, CA 95219 ~ TEL (209) 472-2240 ~ FAX (209) 472-2249		
Copyright © 2015 by Therapeutic Research Center		

Subscribers to the *Letter* can get *PL Detail-Documents*, like this one, on any topic covered in any issue by going to www.PharmacistsLetter.com, www.PrescribersLetter.com, or www.PharmacyTechniciansLetter.com



VIBERZI
PRIOR AUTHORIZATION
 SD DEPARTMENT OF SOCIAL SERVICES
 MEDICAL SERVICES DIVISION

Fax Completed Form to:
866-254-0761
 For questions regarding this
 Prior authorization, call
866-705-5391

SD Medicaid requires that patients receiving a new prescription for Viberzi must meet the following criteria:

- Must be used for treatment of irritable bowel syndrome with diarrhea (IBS-D).
- Must be 18 years of age or older.
- Loperamide and dicyclomine do not require prior authorization.

Part I: RECIPIENT INFORMATION (To be completed by physician's representative or pharmacy):

RECIPIENT NAME:	MEDICAID ID NUMBER:	RECIPIENT DATE OF BIRTH

Part II: PHYSICIAN INFORMATION (To be completed by physician's representative or pharmacy):

PHYSICIAN NAME:	PHYSICIAN DEA NUMBER:	
CITY:	PHONE: ()	FAX: ()

Part III: TO BE COMPLETED BY PHYSICIAN:

Requested Drug:	Diagnosis for this Request:	Failed medications (please list all that apply)
PHYSICIAN SIGNATURE:		DATE:

Part IV: PHARMACY INFORMATION

PHARMACY NAME:	SD MEDICAID PROVIDER NUMBER:
PHONE: ():	FAX: ()
DRUG:	NDC#:

Part V: FOR OFFICIAL USE ONLY

Date: / /	Initials: _____
Approved - Effective dates of PA: From: / /	To: / /
Denied: (Reasons)	



**PCSK9 INHIBITORS
PRIOR AUTHORIZATION**
SD DEPARTMENT OF SOCIAL SERVICES
MEDICAL SERVICES DIVISION

Fax Completed Form to:
866-254-0761
For questions regarding this
Prior authorization, call
866-705-5391

SD Medicaid requires that patients receiving a new prescription for a PCSK9 inhibitor must meet the following criteria:

- Diagnosis of HeFH, HoFH, or clinical atherosclerotic cardiovascular disease with supporting documentation.
- Must be 18 years of age or older for the diagnosis of HeFH or clinical atherosclerotic cardiovascular disease or must be 13 years of age or older for the diagnosis of HoFH.
- Must be on high dose statin therapy for at least 3 months.

Part I: RECIPIENT INFORMATION (To be completed by physician's representative or pharmacy):

RECIPIENT NAME:	MEDICAID ID NUMBER:	RECIPIENT DATE OF BIRTH

Part II: PHYSICIAN INFORMATION (To be completed by physician's representative or pharmacy):

PHYSICIAN NAME:	PHYSICIAN DEA NUMBER:	SPECIALIST INVOLVED IN THERAPY:
CITY:	PHONE: ()	FAX: ()

Part III: TO BE COMPLETED BY PHYSICIAN:

Requested Drug:	Diagnosis for this Request: Provide supporting documentation of diagnosis: Current statin therapy: Member's baseline LDL-C _____ Current LDL-C _____ Goal LDL-C: _____
PHYSICIAN SIGNATURE:	DATE:

Part IV: PHARMACY INFORMATION

PHARMACY NAME:	SD MEDICAID PROVIDER NUMBER:
PHONE: ()	FAX: ()
DRUG:	NDC#:

Part V: FOR OFFICIAL USE ONLY

Date: / /	Initials: _____
Approved - Effective dates of PA: From: / /	To: / /
Denied: (Reasons)	

South Dakota Medicaid
Antipsychotic PA Review

Antipsychotic PA Overview July 2015

253 APPROVALS

371 DENIALS

Review of 371 denials:

326 ultimately approved for original drug requested (appeal process with additional documentation provided by the prescriber)

45 prior authorizations ultimately not approved

19 patients had eligibility issues


12 patients switched to preferred antidepressant

12 patients didn't fill anything


1 patient on a different antipsychotic than the one requested

1 patient on 2 other antipsychotics than the one requested

ANTIPSYCHOTICS TOTAL CLAIMS COST
 JANUARY 2009 - MARCH 2015



ANTIPSYCHOTICS TOTAL PATIENTS/TOTAL RXS JANUARY 2009 - MARCH 2015



SD Medicaid PPI Utilization			
10/29/14 - 10/28/15			
Label Name	Rx Num	Total Reimb Amt	Avg Cost per Script
ACIPHEX DR 20 MG TABLET	3	\$1,244.51	\$414.84
ACIPHEX SPRINKLE DR 10 MG CAP	22	\$10,674.97	\$485.23
ACIPHEX SPRINKLE DR 5 MG CAP	2	\$544.57	\$272.29
DEXILANT DR 30 MG CAPSULE	132	\$27,523.94	\$208.51
DEXILANT DR 60 MG CAPSULE	549	\$115,781.64	\$210.90
ESOMEPRAZOLE MAG DR 20 MG CAP	114	\$26,943.20	\$236.34
ESOMEPRAZOLE MAG DR 40 MG CAP	636	\$161,306.26	\$253.63
FIRST-LANSOPRAZOLE 3 MG/ML	2	\$122.60	\$61.30
FIRST-OMEPRAZOLE 2 MG/ML SUSP	23	\$1,363.30	\$59.27
LANSOPRAZOLE DR 15 MG CAPSULE	428	\$15,520.42	\$36.26
LANSOPRAZOLE DR 30 MG CAPSULE	1948	\$55,995.71	\$28.75
NEXIUM DR 10 MG PACKET	152	\$42,299.73	\$278.29
NEXIUM DR 20 MG CAPSULE	181	\$42,857.81	\$236.78
NEXIUM DR 40 MG CAPSULE	700	\$209,466.59	\$299.24
NEXIUM DR 5 MG PACKET	13	\$2,446.32	\$188.18
OMEPRAZOLE DR 10 MG CAPSULE	237	\$3,633.94	\$15.33
OMEPRAZOLE DR 20 MG CAPSULE	11886	\$122,849.13	\$10.34
OMEPRAZOLE DR 40 MG CAPSULE	3725	\$55,592.71	\$14.92
OMEPRAZOLE-BICARB 40-1,100 CAP	11	\$3,473.80	\$315.80
PANTOPRAZOLE SOD DR 20 MG TAB	148	\$1,207.79	\$8.16
PANTOPRAZOLE SOD DR 40 MG TAB	1546	\$15,285.14	\$9.89
PREVACID 15 MG SOLUTAB	1390	\$443,120.22	\$318.79
PREVACID 30 MG SOLUTAB	634	\$259,242.83	\$408.90
PREVACID DR 30 MG CAPSULE	20	\$6,711.50	\$335.58
PRILOSEC DR 10 MG SUSPENSION	9	\$2,414.40	\$268.27
PRILOSEC DR 2.5 MG SUSPENSION	7	\$1,300.14	\$185.73
PRILOSEC DR 20 MG CAPSULE	1	\$9.47	\$9.47
PROTONIX 40 MG SUSPENSION	2	\$531.78	\$265.89
RABEPRAZOLE SOD DR 20 MG TAB	394	\$12,510.25	\$31.75
5,324 recipients	24915	\$1,641,974.67	

PPI Summary by Age	
Age	Recip Count
0-5	411
6-10	368
11-15	522
16-20	630
21-25	283
26-30	401
31-35	454
36-40	429
41-45	365
46-50	342
51-55	404
56-60	374
61+	341
90% Soltab use ≤ 13	


SD Medicaid Enbrel/Humira Utilization			
10/29/14 - 10/28/15			
Label Name	Rx Num	Total Reimb Amt	Avg Cost per Script
HUMIRA 40 MG/0.8 ML SYRINGE	40	\$138,626.65	\$3,465.67
HUMIRA 40 MG/0.8 ML PEN	217	\$758,209.04	\$3,494.05
HUMIRA PEN CROHN'S-UC-HS START	4	\$39,226.74	\$9,806.69
HUMIRA PEN PSORIASIS START PK	3	\$19,541.65	\$6,513.88
HUMIRA 20 MG/0.4 ML SYRINGE	13	\$41,490.74	\$3,191.60
ENBREL 25 MG KIT	28	\$43,849.09	\$1,566.04
ENBREL 50 MG/ML SYRINGE	31	\$85,497.70	\$2,757.99
ENBREL 50 MG/ML SURECLICK SYR	153	\$495,232.99	\$3,236.82
80 recipients	489	\$1,621,674.60	

Enbrel Diagnoses	
Rheumatoid Arthritis	17
Ankylosing Spondylitis	1
Psoriatic Arthropathy	1
Polyarticular Juv Rheumatoid Arthritis	6
Oth Psoriasis	2
No supporting diagnosis	7
Humira Diagnoses	
Rheumatoid Arthritis	13
Psoriatic Arthropathy	6
Ankylosing Spondylitis	2
Polyarticular Juv Rheumatoid Arthritis	2
Oth Psoriasis	6
Uns Inflammatory Polyarthropathy	2
No supporting diagnosis	15


SD Medicaid Lyrica Utilization			
10/29/14 - 10/28/15			
Label Name	Rx Num	Total Reimb Amt	Avg Cost per Script
LYRICA 100 MG CAPSULE	541	\$200,629.51	\$370.85
LYRICA 150 MG CAPSULE	832	\$290,372.54	\$349.01
LYRICA 200 MG CAPSULE	238	\$90,597.76	\$380.66
LYRICA 225 MG CAPSULE	37	\$11,833.69	\$319.83
LYRICA 25 MG CAPSULE	25	\$9,299.34	\$371.97
LYRICA 300 MG CAPSULE	179	\$57,554.97	\$321.54
LYRICA 50 MG CAPSULE	440	\$159,502.12	\$362.50
LYRICA 75 MG CAPSULE	657	\$212,768.67	\$323.85
513 recipients	2949	\$1,032,558.60	

Label Name	Avg tablets per day
Lyrica 25 mg	2.5
Lyrica 50mg	2.5
Lyrica 75 mg	2
Lyrica 100 mg	2.5
Lyrica 150 mg	2.5
Lyrica 200 mg	2.5
Lyrica 225 mg	2
Lyrica 300 mg	2

SD MEDICAID HYDROCODONE/APAP
TOTAL PATIENTS/TOTAL RXS
JANUARY 2014 - JUNE 2015



SD MEDICAID HYDROCODONE/APAP
TOTAL CLAIMS COST
JANUARY 2014 - APRIL 2015



PRODUCT DETAILS OF OTREXUP (METHOTREXATE)

INDICATIONS AND USE:

- Management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA) who are intolerant of or had an inadequate response to first-line therapy.
- Symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy.

DOSAGE FORMS:

- Injection: Single-dose auto-injector delivering 0.4 mL of methotrexate in the following dosage strengths – 7.5 mg, 10 mg, 15 mg, 20 mg, and 25 mg.

ADMINISTRATION:

- Otrexup is for once weekly subcutaneous use only.
- Administer in the abdomen or thigh.
- Use another formulation of methotrexate for patients requiring oral, intramuscular, intravenous, intra-arterial, or intrathecal dosing, doses less than 7.5 mg per week, doses above 25 mg per week, high-dose regimens, or dose adjustments of less than 5 mg increments.
- Starting doses of methotrexate: RA 7.5 mg once weekly; pJIA: 10 mg/m² once weekly; Psoriasis: 10 to 25 mg once weekly of an oral, intramuscular, subcutaneous, or intravenous formulation.

CONTRAINDICATIONS:

- Pregnancy
- Nursing mothers
- Alcoholism or liver disease
- Immunodeficiency syndromes
- Preexisting blood dyscrasias
- Hypersensitivity to methotrexate

WARNINGS AND PRECAUTIONS:

- Organ system toxicity
- Embryo-fetal toxicity
- May cause impairment of fertility, oligospermia, and menstrual dysfunction
- Monitor complete blood counts, renal function, and liver function tests
- Risks from improper dosing
- Patients with impaired renal function, ascites, or pleural effusions
- Dizziness and fatigue

ADVERSE REACTIONS: Common adverse reactions are nausea, abdominal pain, dyspepsia, stomatitis/mouth sores, rash, nasopharyngitis, diarrhea, liver function test abnormalities, vomiting, headache, bronchitis, thrombocytopenia, alopecia, leucopenia, pancytopenia, dizziness, photosensitivity, and "burning of skin lesions."

COST

- Otrexup – approximately \$570 per month.

References:

1. Otrexup [package insert]. Ewing, NJ: Antares Pharma, Inc.; November 2014.

PRODUCT DETAILS OF DURLAZA (ASPIRIN)

INDICATIONS AND USE:

- Nonsteroidal anti-inflammatory drug indicated to reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina and to reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack
- Use immediate-release aspirin (not Durlaza) in situations where a rapid onset of action is required.

DOSAGE FORMS:

- Capsules: 162.5 mg

ADMINISTRATION:

- The recommended dose 162.5 mg per day with a full glass of water at the same time each day.

CONTRAINDICATIONS:

- Hypersensitivity to nonsteroidal anti-inflammatory drug products.
- Asthma, rhinitis, and nasal polyps.

WARNINGS AND PRECAUTIONS:

- Increased risk of bleeding.

ADVERSE REACTIONS:

- Most common adverse reactions are gastrointestinal.

COST

- Durlaza – approximately \$200 per month.

References:

1. Durlaza [package insert]. North Haven, CT: New Haven Pharmaceuticals, Inc.; September 2015.